Modafinil Explained

Verifiedfields:correct
Watchedfields:correct
Verifiedrevid:800497129
Width:225
Tradename:Provigil, Alertec, Modavigil, others
Dailymedid:Modafinil
Pregnancy Au:D
Dependency Liability:Relatively low
Addiction Liability:Low
Routes Of Administration:By mouth
Class: stimulant
eugeroic
Atc Prefix:N06
Atc Suffix:BA07
Legal Au:S4
Legal Au Comment:[1]
Legal Br:B1
Legal Br Comment:[2]
Legal Ca:Rx-only
Legal Ca Comment:[3]
Legal Uk:POM
Legal Uk Comment:[4]
Legal Us:Schedule IV
Legal Us Comment:[5]
Protein Bound:62.3%
Metabolism:Liver (primarily via amide hydrolysis); CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5 involved[6]
Elimination Half-Life:[7]
Excretion:Urine (80%)
Cas Number:68693-11-8
Pubchem:4236
Iuphar Ligand:7555
Drugbank:DB00745
Chemspiderid:4088
Unii:R3UK8X3U3D
Kegg:D01832
Chebi:31859
Chembl:1373
Synonyms:CRL-40476; Diphenylmethyl-sulfinylacetamide
Iupac Name:2-(diphenylmethanesulfinyl)acetamide
C:15
H:15
N:1
O:2
S:1
Smiles:O=S(C(c1ccccc1)c2ccccc2)CC(=O)N
Stdinchi:1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)
Stdinchikey:YFGHCGITMMYXAQ-UHFFFAOYSA-N

Modafinil, sold under the brand name Provigil among others, is a wakefulness-promoting medication used primarily to treat narcolepsy, [8] [9] a sleep disorder characterized by excessive daytime sleepiness and sudden sleep attacks. Modafinil is also approved for stimulating wakefulness in people with sleep apnea and shift work sleep disorder.[8] It is taken by mouth.[8] Modafinil is not approved by the US Food and Drug Administration (FDA) for use in people under 17 years old.

Modafinil has potential for causing severe allergic reactions, mental (psychiatric) effects,[8] hypersensitivity, adverse interactions with prescription drugs, and misuse or abuse.[8] [9] Modafinil may harm the fetus if taken during or two months prior to pregnancy.[10]

While modafinil is used as a cognitive enhancer or "smart drug" among healthy individuals seeking improved focus and productivity, its use outside medical supervision raises concerns regarding potential misuse or abuse.[5] Research on the cognitive enhancement effects of modafinil in non-sleep-deprived individuals has yielded mixed results, with some studies suggesting modest improvements in attention and executive functions, while others show no significant benefits or even a decline in cognitive functions at high doses.

Usage

Medical

Sleep disorders

Modafinil, a eugeroic or wakefulness-promoting drug, is primarily used for treating narcolepsy, a sleep disorder characterized by excessive daytime sleepiness and sudden sleep attacks.[11] Being a central nervous system (CNS) stimulant (psychostimulant) itself, modafinil has lower addictive potential than classical psychostimulants, such as amphetamines, cocaine or methylphenidate,[12] [13] [14] but still produces psychoactive, euphoric, and subjective effects typical of classical stimulants.[5]

Narcolepsy causes a strong urge to sleep during the day and can include symptoms like cataplexy (sudden muscle weakness), sleep paralysis (inability to move or speak while falling asleep or waking up), and hallucinations. Narcolepsy is linked to a lack of the brain chemical hypocretin (orexin), primarily produced in the hypothalamus.[15] [16] Modafinil is not a cure for narcolepsy, but it can help manage the symptoms. While modafinil is primarily used to treat excessive sleepiness, it may also help reduce the frequency and severity of cataplexy attacks in some people. Modafinil is approved for management of narcolepsy with or without cataplexy. However, it is not specifically approved for the treatment of cataplexy.[17]

Modafinil is also prescribed for shift work sleep disorder.

Modafinil is also used to overcome excessive daytime sleepiness caused by obstructive sleep apnea, though it is recommended that people with apnea use continuous positive airway pressure (CPAP) therapy, that is a sleep breathing apparatus to prevent apnea, before starting modafinil.[18] [19]

Modafinil's use varies by region. In the US, it is approved for adult narcolepsy, shift work sleep disorder, and obstructive sleep apnea, but not for children. In the UK and the EU, since 2014, it is approved solely for narcolepsy, including in children (pediatric narcolepsy), with its use for other conditions restricted by the European Medicines Agency.[20] [21]

both the French and the American Academy of Sleep Medicine strongly recommend modafinil as the first-choice treatment for narcolepsy.[22] In Europe, modafinil is considered one of the primary drugs recommended for treating narcolepsy according to the guidelines.[23]

Multiple sclerosis-related fatigue

The National Institute for Health and Care Excellence (NICE) in the UK, along with various non-governmental organizations focused on multiple sclerosis (MS), endorse the off-label use of modafinil to alleviate fatigue associated with MS.[24] [25]

MS-related fatigue is a common and often debilitating symptom experienced by people with multiple sclerosis.[26] [27] It can significantly impact their daily functioning, quality of life, and ability to perform everyday activities. When prescribed for MS-related fatigue management, modafinil works by promoting wakefulness and increasing alertness without causing drowsiness or disrupting nighttime sleep. People with multiple sclerosis often report increased energy levels, reduced feelings of tiredness, improved cognitive function, and an overall improvement in their quality of life when taking modafinil. While modafinil can provide relief from MS-related fatigue symptoms, it does not treat the underlying cause or cure MS itself. The primary goal of using modafinil in MS is symptom management and improving daily functioning. The effects of modafinil on other aspects of MS-related fatigue, such as severity and cognitive function, are less clear.

While modafinil has been shown to be effective in managing fatigue in people with MS, optimal dosing and treatment schedules are not well established.[28] [29] [30] [31]

Attention deficit hyperactivity disorder

Modafinil is occasionally prescribed off-label for individuals with attention deficit hyperactivity disorder (ADHD).[32] [33] [34] It has not consistently shown efficacy in treating adult ADHD, especially when compared to other treatments such as lisdexamfetamine.[35] In children, modafinil is efficient in treating ADHD symptoms.[36] [37]

Given its approved status in the US to treat narcolepsy, physicians can also prescribe modafinil for off-label uses, such as treating ADHD in both children and adults.[38] [39]

The Canadian Network for Mood and Anxiety Treatments (CANMAT) suggests modafinil as a second-line choice for ADHD, after the first-line choices such as bupropion are exhausted.[40]

Bipolar disorder

Modafinil is used off-label as an adjunctive treatment (i.e., in combination therapy) for acute depressive phase in bipolar disorder.[41] [42] [43] The depressive phase of bipolar disorder may feature excessive sleepiness and fatigue. Adjunctive treatment with modafinil can be used as an augmentation for the main treatment to increase its effect and is safe and effective, especially for people who do not respond well to standard antidepressants.[44] [45] [46] Modafinil does not significantly increase the risk of mood switch to mania or suicide attempts in people with bipolar disorder.[47] [44] Modafinil may also have cognitive benefits in people with bipolar disorder who are in a remission state.[48] [46]

Whereas modafinil and armodafinil are approved for narcolepsy, they have been repurposed as adjunctive treatments to alleviate symptoms of acute depressive phase in people with bipolar disorder.[49] Drug repurposing in psychiatry is a strategy for discovering new uses for drugs that have already been approved or tested in clinical trials for other illnesses. As such, drug repurposing is a rapid, cost-effective, and reduced-risk strategy for the development of new treatment options for psychiatric disorders.[49] 2021 meta-analysis concluded that add-on modafinil and armodafinil were more effective than placebo on response to treatment, clinical remission, and reduction in depressive symptoms, with only minor side effects, but the effect sizes are small and the quality of evidence is therefore low, limiting the clinical relevance of the evidence.[49] [50] Very low rates of mood swing (a change in mood from one extreme to another)[47] [51] have been observed with modafinil and armodafinil in depressive phase of bipolar disorder.[52]

Occupational

See also: List of drugs used by militaries and Space medicine.

Modafinil was used by the French Foreign Legion,[53] U.S. Air Force,[54] [55] and U.S. Marine[56] infantry during the Gulf War to enhance "operational tempo" (a term that denotes the speed and intensity at which military operations or activities are executed), aiming to optimize the overall performance and efficiency of the unit.[57] [58]

Armed forces in various countries, including the United States, the United Kingdom, India, and France, have considered modafinil as an alternative to traditional amphetamines for managing sleep deprivation in combat or extended missions.[59] The US military approved modafinil for specific Air Force missions, replacing amphetamines for fatigue management.[60] The use of modafinil in military contexts without sleep deprivation is not recommended due to inconclusive evidence on its cognitive enhancement benefits and potential risks of adverse effects.

Modafinil is also available to astronauts aboard the International Space Station for the management of fatigue caused by circadian dyssynchrony in orbit.[61]

Non-medical

Modafinil has been used non-medically as a "smart drug"[62] [63] by various groups, including students,[64] [65] [66] office workers, transhumanists,[67] [68] and professionals in various sectors. Its use is attributed by these individuals to its potential for enhancing attention, cognitive capabilities, and alertness.[69] [70]

The effectiveness of modafinil as cognitive enhancer is still debated. Some studies suggest significant increases in cognitive abilities, while others indicate mild to non existent cognitive improvements.[71] [41] [72] In some cases, it has even been associated with impairments in certain cognitive functions.[73] [74] It has been shown that modafinil's positive impact on cognitive abilities is more noticeable on sleep deprived individuals.[75] Therefore, in people who are not sleep-deprived, the potential of modafinil as a cognitive enhancer may be limited.[76]

Available forms

Modafinil is commercially available in and oral tablet forms. Additionally, it is offered as the (R)-enantiomer, known as armodafinil, and as a prodrug named adrafinil.[77]

Contraindications

Modafinil is contraindicated during pregnancy and 2 months before getting pregnant. Women who take modafinil should not become pregnant, and, additionally, should be aware that modafinil reduces effectiveness of hormonal contraceptives, increasing chances of getting pregnant.[9] [78] Modafinil therapy during pregnancy increases the risk of birth defects,[10] [79] [80] [81] such as with congenital torticollis, hypospadias, and congenital heart defects.

Modafinil is contraindicated for individuals with known hypersensitivity to either modafinil or armodafinil.

Modafinil is also contraindicated in certain cardiac conditions, including uncontrolled moderate to severe hypertension, arrhythmia, cor pulmonale, and in cases with signs of CNS stimulant-induced mitral valve prolapse or left ventricular hypertrophy.[82] [83] The package insert in the United States cautions about using modafinil in people with a documented medical history of left ventricular hypertrophy or those diagnosed with mitral valve prolapse who have previously exhibited symptoms associated with the mitral valve prolapse syndrome while undergoing treatment involving central nervous system stimulants.[84] The reasons why modafinil is contraindicated in certain cardiac conditions are because modafinil affects the autonomic nervous system and, in particular, exerts significant effects on autonomic cardiovascular regulation, leading in some people to notable increases in heart rate and blood pressure. These substantial changes in the autonomic system warrant careful consideration when prescribing modafinil to people with pre-existing cardiovascular conditions.[85] The increase in heart rate and blood pressure can worsen the symptoms of such pre-existing conditions as hypertension, arrhythmia, and cor pulmonale. These changes in the autonomic system induced by modafinil can increase the risk of heart attack, stroke, and heart failure. Modafinil can stimulate the release of norepinephrine and epinephrine, hormones that activate the sympathetic nervous system. This can cause vasoconstriction, which is the narrowing of blood vessels, and increase the heart's workload, which is not desired in people with pre-existing heart conditions. In particular, modafinil can worsen the consequences of mitral valve prolapse or left ventricular hypertrophy, which are structural abnormalities of the heart. These can affect the blood flow and oxygen delivery to the heart and other organs.[86]

Modafinil is also contraindicated in people with congenital problems like galactose intolerance, lactase deficiency, or glucose-galactose malabsorption.[87] [88] [89]

Adverse effects

Modafinil is generally well-tolerated but can have potential risks and side effects. Common adverse effects of modafinil, experienced by less than 10% of users, include headaches, nausea, and reduced appetite.[90] Anxiety, insomnia, dizziness, diarrhea, and rhinitis are also reported in 5% to 10% of users.[91] Psychiatric reactions have occurred in individuals with and without a preexisting psychiatric history.[92]

No significant changes in body weight have been observed in clinical trials, although decreased appetite and weight loss have been noted in children and adolescents.[93] Modafinil can cause a slight increase in aminotransferase enzymes, indicative of liver function, but there is no evidence of serious liver damage when levels are within reference ranges.[94]

Rare but serious adverse effects include severe skin rashes and allergy-related symptoms. Between December 1998 and January 2007, the FDA received reports of six cases of severe cutaneous adverse reactions, including erythema multiforme, Stevens–Johnson syndrome, toxic epidermal necrolysis, and DRESS syndrome. The FDA has issued alerts regarding these risks and also noted reports of angioedema and multi-organ hypersensitivity reactions in postmarketing surveillance.[95] [96] In 2007, the FDA required Cephalon to modify the Provigil leaflet to include warnings about these serious conditions. The long-term safety and effectiveness of modafinil have not been conclusively established.

The FDA does not endorse modafinil for children's medical conditions due to an increased risk of rare but serious dermatological toxicity, manifested as Stevens–Johnson syndrome which is a type of severe skin reaction.[97] [98] [99] However, in Europe, modafinil may be prescribed for treating narcolepsy in children.

Drug tolerance

Extensive clinical research has not demonstrated drug tolerance, defined as a reduction in response, to wakefulness-promoting and anti-fatigue properties of modafinil, even with therapeutic use extending up to 40 weeks.[100] [101] [102]

While modafinil is generally found to be safe and significant adverse effects are rare, including in pediatric narcolepsy cases (sleep disorders in children), there is evidence that long-term usage can lead to tolerance in some individuals. This necessitates higher doses to maintain the same level of cognitive enhancement or relief from sleepiness.

People with current or past substance addictions and those with a family history of addiction are particularly at risk for developing tolerance.

The mechanisms driving tolerance to modafinil, which may involve its impact on dopamine and norepinephrine levels in the brain, are not fully understood.

Repeated administration of modafinil for off-label use, such as increased alertness and cognitive-enhancing effects in sleep deprivation, can lead to drug tolerance, which means that the effectiveness of the drug may decrease over time. Still, modafinil therapy as a eugeroic agent to treat narcolepsy does not typically lead to drug tolerance, i.e., the effectiveness does not usually decrease on prolonged use, although individual responses may vary.[103] [104]

Addiction and dependence

Despite being a CNS stimulant, the addiction and dependence liabilities of modafinil are considered low.[105] [106] The exact mechanisms of action of modafinil are not known, and it is believed that pharmacological profile of modafinil is different from that of the classical stimulants such as cocaine or amphetamine.[12] Although modafinil shares biochemical mechanisms with stimulant drugs, it is less likely to have mood-elevating properties. The similarities in effects with caffeine are not clearly established.[12] [107] Unlike other stimulants, modafinil does not induce a strong subjective feeling of pleasure or reward, which is commonly associated with euphoria, an intense feeling of well-being.[18] Euphoria is a potential indicator of drug abuse, which is the compulsive and excessive use of a substance despite adverse consequences.[108] In comparison to classical stimulants, modafinil exhibits a low propensity for abuse, as it lacks significantly expressed pleasurable or euphoric effects.[18] Albeit to a lower degree than classical stimulants, modafinil still produces psychoactive, euphoric, and subjective effects typical for abused stimulants.[5] [8]

Modafinil was not observed to promote overuse or misuse, even in people who have a history of cocaine addiction.[109] Despite the initial belief that modafinil carried no abuse potential, emerging evidence suggests that it works at the same neurobiological mechanisms as other addictive stimulants. Consequently, there exists a potential risk of modafinil abuse, necessitating prudent consideration and caution when prescribing or using this medication.[76] Modafinil exhibits a lower response on the amphetamine scale of the addiction research center inventory, suggesting reduced propensity for abuse compared to amphetamine.[110]

The US Drug Enforcement Administration has classified modafinil as a Schedule IV controlled substance;[105] the medicine is recognized for having valid medical uses with low addiction potential. The International Narcotics Control Board does not classify it as a narcotic or a psychotropic substance.[111] [112]

Overdose

An overdose of modafinil can lead to a range of symptoms and complications. Psychiatric symptoms may include psychosis, mania, hallucinations, and suicidal ideation, which can occur even in individuals without a history of mental illness and may persist after discontinuation of the drug.[113] Neurological complications, such as seizures, tremors, dystonia, and dyskinesia, may arise from modafinil's interaction with various neurotransmitter systems.

Allergic reactions such as rash, angioedema, anaphylaxis, and Stevens–Johnson syndrome may be triggered by an immunological response to modafinil or its metabolites.[114] [115] Cardiovascular complications like hypertension, tachycardia, chest pain, and arrhythmias may also be observed due to modafinil's sympathomimetic action.[113]

In animal studies, the median lethal dose (LD50) of modafinil varies among species and depends on the route of administration. In mice and rats, the LD50 is approximately if administered via an injection, but the oral LD50 for rats is .[116] [117] The LD50 value for humans have not been established. Human clinical trials have involved total daily doses up to for 7–21 days. Acute one-time total overdoses up to have not been life-threatening but resulted in symptoms like agitation, insomnia, tremor, palpitations, and gastrointestinal disturbances.[118]

The management of modafinil overdose involves supportive care, monitoring of vital signs, and treatment of specific complications. In cases of recent consumption, activated charcoal, gastric lavage, or hemodialysis may be used.[113] There is no specific antidote for modafinil overdose.[119] [120] The main way to deal with modafinil overdose is supportive care, which includes sedating the patient and stabilizing their blood pressure, and muscle activity in case of manifestations such as agitation or tremor.[118]

Interactions

Some of the drugs that frequently interact with modafinil include aripiprazole (an antipsychotic), amphetamine (including its enantiomers and salts; stimulants), aspirin, diphenhydramine (an antihistamine), and others.[121]

Modafinil is a weak to moderate inducer of CYP3A4[122] [123] and a weak inhibitor of CYP2C19,[7] enzymes of the cytochrome P450 group of enzymes.[91] Modafinil also induces or inhibits other cytochrome P450 enzymes. One in vitro study predicts that modafinil may induce the cytochrome P450 enzymes CYP1A2, CYP3A4, and CYP2B6, as well as may inhibit CYP2C9 and CYP2C19. However, other in-vitro studies find no significant inhibition of CYP2C9.[7] [124] Modafinil may induce P-glycoprotein, which may affect drugs transported by P-glycoprotein, such as digoxin.[125] It was clinically found that modafinil affects pharmacodynamics of drugs which are metabolized by CYP3A4 and other enzymes of the cytochrome P450 family, so that interactions of modafinil with these drugs were observed in real people, rather than being predicted in a lab setting.[122] For instance, it was observed that induction of CYP3A4 by modafinil affects metabolism of the following medications and endogenous substances:

Pharmacology

Pharmacodynamics

Modafinil activity profile
Site Potency Type Species Refs



Ki
Ki
IC50a
IC50a 		Human
Rat
Human
Rat 		[132] [133]

[134] [135]
>
>

Ki
Ki
IC50a
IC50a 		Human
Rat
Human
Rat


>

>
> 		Ki
Ki
IC50a
IC50a 		Human
Rat
Human
Rat


>
b
b 		Ki
Ki
EC50a 		Human
Rat
Rat
[136]
Footnotes: a = Functional activity, not binding inhibition. b = Armodafinil at D2High. Notes: No activity at a variety of other assessed targets.

The precise mechanism of action of modafinil for narcolepsy and other sleep disorders remains unclear.[8] [137] [138] [139] Although modafinil may have interactions with neurotransmitter systems, its exact mode of action is not fully understood.[137] [140]

From laboratory research, modafinil has little to no affinity for serotonin or norepinephrine transporters and does not directly interact with these systems.[91] [139] However, studies have shown that elevated concentrations of norepinephrine and serotonin can occur as an indirect effect following modafinil administration due to increased extracellular dopamine activity.[139] [91] Unlike traditional psychostimulant drugs, such as cocaine or amphetamine, modafinil shows low potential for causing euphoria due to differences in how it interacts with dopamine transporters at a cellular level.[137] [139] [140]

In addition to its influence on dopaminergic pathways, modafinil may impact other neurotransmitter systems, such as orexin(hypocretin).[139] Orexin neurons play a crucial role in promoting wakefulness and regulating arousal states. Modafinil may increase signaling within hypothalamic orexin pathways, potentially contributing to its wake-promoting effects.[91] [139]

Pharmacokinetics

Cmax (peak levels) occurs approximately 2 to 3 hours after modafinil administration.[7] Food slows absorption of modafanil, but does not affect the total area under the curve (AUC). In vitro measurements indicate that 60% of modafinil is bound to plasma proteins at clinical concentrations of the drug. This percentage changes very little when the concentration of modafinil is varied.[141]

Renal excretion of unchanged modafinil usually accounts for less than 10% of an oral dose. This means that when modafinil is taken by mouth, less than 10% of the drug is eliminated from the body through the urine without being metabolized by the liver or other organs. The rest of the drug is either metabolized or excreted through other routes, such as feces or bile.[7]

The two major circulating metabolites of modafinil are modafinil acid (CRL-40467) and modafinil sulfone (CRL-41056). Both of these metabolites have been described as inactive, and neither appears to contribute to the wakefulness-promoting effects of modafinil.[98] [142] However, modafinil sulfone does appear to possess anticonvulsant effects, a property that it shares with modafinil.[98] [143]

Elimination half-life is in the range of 10 to 12 hours,[7] [141] subject to differences in sex,[78] in cytochrome P450 genotypes, liver function and renal function. Modafinil is metabolized mainly in the liver,[7] and its inactive metabolites are excreted in the urine. Urinary excretion of the unchanged drug is usually less than 10%, but can range from 0% to as high as 18.7%, depending on the factors mentioned.[141]

Modafinil exhibits sex-specific pharmacokinetic differences. It demonstrates higher bioavailability in women compared to men. The mean Cmax is higher in women than in men, vs. (p < 0.05), following a single oral dose of modafinil. This difference persists even after adjusting for body weight (vs.). The clearance of modafinil is 30% higher in men than in women, and plasma concentrations after a single dose are significantly higher in women than in men. These sex-specific pharmacokinetic differences may have implications for the efficacy and safety of modafinil.

Chemistry

Enantiomers

Modafinil is a racemic mixture of two enantiomers, armodafinil ((R)-modafinil) and esmodafinil ((S)-modafinil).[144]

Detection in body fluids

Modafinil and/or its major metabolite, modafinil acid, may be quantified in plasma, serum, or urine to monitor dosage in those receiving the drug therapeutically, to confirm a diagnosis of poisoning in hospitalized patients, or to assist in the forensic investigation of a vehicular traffic violation.[145] Instrumental techniques involving gas or liquid chromatography are usually employed for these purposes.[72] [146] [147] In 2011, modafinil was not tested for by common drug screens (except for anti-doping screens) and is unlikely to cause false positives for other chemically unrelated drugs such as substituted amphetamines.[135]

Reagent testing can screen for the presence of modafinil in samples.

Structural analogs

Many derivatives and structural analogs of modafinil have been synthesized.[13] [150] [151] Examples include adrafinil, CE-123, fladrafinil (CRL-40941; fluorafinil), flmodafinil (CRL-40940; bisfluoromodafinil, lauflumide), and modafinil sulfone (CRL-41056).[152] [13]

History

Modafinil was developed in France by neurophysiology professor Michel Jouvet and Lafon Laboratories. It is part of a series of benzhydryl sulfinyl compounds, including adrafinil, initially used as a treatment for narcolepsy in France in 1986. Modafinil, the primary metabolite of adrafinil,[153] has been prescribed in France since 1994 under the name Modiodal, and in the United States since 1998 as Provigil. Unlike modafinil, adrafinil does not have FDA approval and was withdrawn from the French market in 2011.[154]

The FDA approved modafinil in 1998 for narcolepsy treatment, and later for shift work sleep disorder and obstructive sleep apnea in 2003.[155] [156] It was approved in the UK in December 2002. In the United States, modafinil is marketed by Cephalon,[157] who acquired the rights from Lafon and purchased the company in 2001.[157]

Cephalon introduced armodafinil, the (R)-enantiomer of modafinil, in the United States in 2007. Generic versions of modafinil became available in the US in 2012 after extensive patent litigation.[158] [159]

Society and culture

Modafinil is not approved for use by children in multiple jurisdictions.[160] [161]

Legal status

Australia

In Australia, modafinil is considered to be a Schedule 4 prescription-only medicine. This means that it is a drug with a perceived low potential for abuse and low risk of dependence; still, the use of Schedule 4 drugs in Australia is restricted to those who have a valid prescription from a medical practitioner; import from abroad is illegal.[162]

Canada

In Canada, modafinil is not specifically included in the lists of controlled drugs and substances specified within the Controlled Drugs and Substances Act.[163] However, it is classified as a Schedule F prescription drug.[164] [165] [166] This means that modafinil can only be obtained legally with a valid prescription from a licensed health care practitioner in Canada, and the import of modafinil to Canada from other countries is subject to restrictions: importing prescription drugs without an import permit may result in the seizure of the drugs at the border, the refusal of entry of the drugs into Canada, or prosecution.[167]

China

In mainland China, modafinil is strictly controlled like other stimulants such as amphetamines and methylphenidate. It is classified as Class I psychotropic drug. This classification means that modafinil is considered to have a high potential for abuse and dependence, and is therefore subject to strict regulation and control. As a result, modafinil is only available by prescription and cannot be purchased over the counter. In order to obtain a prescription for modafinil, a patient must have a valid medical reason for using the drug, such as narcolepsy or obstructive sleep apnea. Additionally, the prescription must be written by a licensed physician and filled at a licensed pharmacy. The use of modafinil for non-medical purposes, such as with the aim to improve cognitive performance or to stay awake for long periods of time, is strictly prohibited and can result in legal consequences.[168] [169]

Europe

In Denmark, modafinil is a prescription drug but not listed as a controlled substance. According to the Danish Medicines Agency, modafinil is approved for use in the treatment of narcolepsy, still, importing modafinil to Denmark is considered illegal without a valid prescription.[170] [171] [172] [173]

In Finland, modafinil is a prescription drug but not listed as a controlled substance. Finland is a member of the European Union, and it is illegal to import prescription medicine from outside the European Union unless the person has a valid prescription.[174] [175] [176]

In the Republic of Moldova, modafinil is classified as a psychotropic drug (included in table III list 3 which is the list of psychotropic substances as defined by the Government of Moldova) and is available by prescription.[177] Importation of modafinil may be considered illegal and subject to severe penalties, even if you have a prescription.[178] For example, on June 29, 2017, Moldovan postal officers discovered 60 tablets of Modalert (200 mg modafinil tablets) in a parcel sent from India to a resident in Chișinău, Moldova. The prohibited substance was detected during a routine scan and was seized as illegal. The authorities were notified of the incident and the recipient was charged with criminal penalties.[179] [180] In the Transnistria region of Moldova, modafinil is completely prohibited, due to application of the legislation similar to that of Russia where modafinil is completely prohibited and is in the same list as narcotics. Possession or an attempt to bring modafinil to Transnistria potentially leads to imprisonment.

In Romania, modafinil is classified as a stimulant doping agent and is prohibited in sports competitions.[181] In 2022, laws were passed making its importation or sale a felony, punishable by three to seven years in jail.[182] Simple possession for personal use may result in a fine and confiscation.

In Sweden, modafinil is classified as a schedule IV substance, which means that it is considered to have low potential for abuse and low risk of dependence. Still, possession is illegal without prescription.[183]

In the United Kingdom, it is not listed in Misuse of Drugs Act, so possession is not illegal, but a prescription is required.[184]

Mexico

In Mexico, modafinil is not listed as a controlled substance, in the National Health Law, and can be purchased in pharmacies without prescription.[185]

Japan

In Japan, modafinil is Schedule I psychotropic drug. This means that it is considered to have a high potential for abuse and dependence, and is therefore subject to strict regulations. The use of Schedule I drugs in Japan is generally prohibited, except under certain circumstances, such as for medical purposes. It can only be prescribed by a doctor. It cannot be imported or exported without a permit. It cannot be used while driving or operating machinery.[186] [187] Cephalon licensed Alfresa Corporation to produce, and Mitsubishi Tanabe Pharma to sell modafinil products under the trade name Modiodal in Japan.[188] There have been arrests of people who imported modafinil for personal use.[189] [190]

Russia

In Russia, starting from May 18, 2012, modafinil is Schedule II controlled substance. Being classified as a schedule II controlled substance in Russia means that it is seen as a drug with a high potential for abuse and dependence. This classification imposes strict regulations on the production, distribution, and use of modafinil. Possession of a few modafinil pills can lead to three to ten years imprisonment. Modafinil is not approved for medical use in Russia and cannot be bought even in pharmacies. It also cannot be imported from abroad, even if you have a prescription issued outside Russia.[191] [192] There are multiple cases of criminal proceedings initiated against Russian residents who tried to import modafinil by mail from abroad.[193] [194]

South Africa

In South Africa, modafinil is Schedule V substance, which means that it is legal to use modafinil in South Africa, but only with a valid prescription from a licensed medical practitioner.[195]

United States

In the United States, modafinil is classified as a schedule IV controlled substance[105] under US federal law.[196] This means that the drug has a low potential for abuse and dependence compared to other controlled substances. However, it still requires a prescription from a licensed healthcare provider to obtain.[196]

It is illegal to import modafinil to the United States without a Drug Enforcement Administration (DEA)-registered importer and a prescription.[197] Individuals may legally bring modafinil into the US from a foreign country for personal use, limited to 50 dosage units, with a prescription and proper declaration at the border.[198] Under the Pure Food and Drug Act, marketing drugs for off-label uses is prohibited.[199] Cephalon, the manufacturer of Provigil, faced legal issues for promoting off-label uses and paid significant fines in 2008.[200]

Brand names

Modafinil is sold under a variety of brand names worldwide, including Alertec, Alertex, Altasomil, Aspendos, Bravamax, Forcilin, Intensit, Karim, Mentix, Modafinilo, Modalert, Modanil, Modasomil, Modvigil, Modiodal, Modiwake, Movigil, Provigil, Resotyl, Stavigile, Vigia, Vigicer, Vigil, Vigimax, Waklert, and Zalux.[201]

Economics

Originally developed in the 1970s by French neuroscientist Michel Jouvet and Lafon Laboratories, modafinil has been prescribed in France since 1994,[202] [23] and was approved for medical use in the United States in 1998.[23]

Concerns have been raised about the growing use of modafinil as a "smart drug" or cognitive enhancer among healthy individuals who use it with the aim to improve concentration and memory. In 2003, modafinil sales were skyrocketing, with some experts concerned that it had become a tempting pick-me-up for people looking for an extra edge in a productivity-obsessed society. The cost of modafinil varied depending on factors such as location and insurance coverage, still, in 2004, the price of modafinil in the US was around $120 or more per monthly supply. However, the availability of generic versions has increased since then and may have driven down prices.[203] [204] [205]

In 2020, modafinil was the 302nd most commonly prescribed medication in the United States, with just over prescriptions.[206]

the global sales figures for modafinil are not known. Still, modafinil sold under the brand name Provigil accounted for over 40% of Cephalon's global turnover for several years, according to the information published in 2020.[207]

Patent protection and litigation

Modafinil's patent history involves several key developments. The original patent,, was granted to Laboratoire L. Lafon in 1990, covering the chemical compound of modafinil. This patent expired in 2010.[208] In 1994, Cephalon filed a patent for modafinil in the form of particles of a defined size, represented by, which expired in 2015.[209]

Following the nearing expiration of marketing rights in 2002, generic manufacturers, including Mylan and Teva, applied for FDA approval to market a generic form of modafinil, leading to legal challenges by Cephalon regarding the particle size patent.[210] The patent RE 37,516 was declared invalid and unenforceable in 2011.[211]

In addition, Cephalon entered agreements with several generic drug manufacturers to delay the sale of generic modafinil in the US. These agreements were subject to legal scrutiny and antitrust investigations, culminating in a ruling by the Court of Appeals in 2016, which found that the settlements did not violate antitrust laws.[212]

Sports

The regulation of modafinil as a doping agent has been controversial in the sporting world, with high-profile cases attracting press coverage since several prominent American athletes tested positive for the substance. Some athletes who used modafinil protested that the drug was not on the prohibited list at the time of their offenses.[213] However, the World Anti-Doping Agency (WADA) maintains that modafinil was related to already-banned substances. The Agency added modafinil to its list of prohibited substances on August 3, 2004, ten days before the start of the 2004 Summer Olympics.[214]

Several athletes, such as sprinter Kelli White in 2003,[215] cyclist David Clinger[216] and basketball player Diana Taurasi[217] in 2010, and rower Timothy Grant in 2015,[218] were accused of using modafinil as a performance-enhancing doping agent. Taurasi and another player—Monique Coker, tested at the same lab—were later cleared.[219] Kelli White, who tested positive after her 100m victory at the 2003 World Championships in Paris, was stripped of her gold medals.[220] She claimed that she used modafinil to treat narcolepsy, but the International Association of Athletics Federations (IAAF) ruled that modafinil was a performance-enhancing drug.[220]

The BALCO scandal brought to light an unsubstantiated (but widely published) account of Major League Baseball's all-time leading home-run hitter Barry Bonds' supplemental chemical regimen that included modafinil in addition to anabolic steroids and human growth hormone.[221]

Social views

The use of modafinil as a supposed cognitive enhancer may be considered as cheating, unnatural, or risky.[222] The University of Sussex explained that it is a prescription drug and the decision should be made by the doctor on whether to prescribe modafinil to a student.[223] As a matter of bioethics, the US President's Council on Bioethics argued that excellence achieved through the use of drugs like modafinil is "cheap" as it obviates the need for hard work and study, and is not fully authentic because the excellence is partly attributable to the drug, not the individual.[224] Alternately, people in environments like Wall Street trading may not view the use of modafinil as cheating, believing that if modafinil can give them an edge and they are aware of the risks involved, it should not be considered as cheating.[225] Due to such varying views, modafinil users for narcolepsy may cope with stigma by hiding, denying, or justifying their use, or by seeking support from others who share their views or experiences.[226] [227]

Research

Psychiatric conditions

Major depressive disorder

Modafinil has been studied in the treatment of major depressive disorder.[228] [229] [230] In a 2021 systematic review and meta-analysis of randomized controlled trials of psychostimulants for depression, modafinil and other stimulants such as methylphenidate and amphetamines improved depression in traditional meta-analysis. However, when subjected to network meta-analysis, modafinil and most other stimulants did not significantly improve depression, with only methylphenidate remaining effective. Modafinil and other stimulants likewise did not improve quality of life in the meta-analysis, although there was evidence for reduced fatigue and sleepiness with modafinil and other stimulants. While significant effectiveness of modafinil for depression has been reported by particular trials,[231] [232] reviews and meta-analyses note that the effectiveness of modafinil for depression is limited, the quality of available evidence is low, and the results are inconclusive.[233] [234]

Attention deficit hyperactivity disorder (research)

Modafinil was considered for the treatment of ADHD because of its lower abuse potential than conventional psychostimulants like methylphenidate and amphetamines.[235] In 2008, an application to market modafinil for pediatric ADHD was submitted to the Food and Drug Administration in the US.[236] [46]

However, evidence of modafinil for treatment of adult ADHD is mixed, and a 2016 systematic review of alternative drug therapies for adult ADHD did not recommend its use in this context.[237] In a later large phase 3 clinical trial of modafinil for adult ADHD, modafinil was not effective in improving symptoms, there was also a high rate of side effects (86%) and discontinuation (47%).[238] The poor tolerability of modafinil in this study was possibly due to the use of high doses . Another reason for the denial of the approval was due to concerns about rare but serious dermatological toxicity in Stevens–Johnson syndrome.

Substance dependence

Modafinil was studied for the treatment of stimulant dependence, but the results are mixed and inconclusive.[13] [239] Modafinil is not a controlled substance in some countries, unlike other medications, such as bupropion, which is also used to treat depression and nicotine dependence.[240] The clinical trials that have tested modafinil as a treatment for stimulant abuse have failed to demonstrate its efficacy and the optimal dose and duration of modafinil treatment remain unclear, and modafinil is not a recommended treatment for stimulant abuse.[240] A 2024 review found that modafinil was ineffective for amphetamine-type stimulant use disorder.[241]

Schizophrenia

Modafinil and armodafinil were studied as a complement to antipsychotic medications in the treatment of schizophrenia. They showed no effect on positive symptoms or cognitive performance.[242] A 2015 meta-analysis found that modafinil and armodafinil may slightly reduce negative symptoms in people with acute schizophrenia, though they do not appear useful for people with the condition who are stable, with high negative symptom scores.[243] Among medications demonstrated to be effective for reducing negative symptoms in combination with antipsychotics, modafinil and armodafinil are among the smallest effect sizes.[244]

Abstinence in cocaine addiction

Modafinil is researched to determine whether it might improve abstinence in people with cocaine addiction.[245]

Cognitive enhancement

A 2019 review conducted on the potential nootropic effects of modafinil in healthy, non-sleep-deprived individuals revealed the following:[246] a) while studies using basic testing paradigms demonstrated that modafinil enhances executive function, only half of these studies showed improvements in attention, learning, and memory, with a few studies even reporting impairments in divergent creative thinking; b) modafinil displayed small levels of enhancement in attention, executive functions, and learning abilities; c) no substantial side effects or mood changes were observed; d) the available evidence showed limited evidence for modafinil as a cognitive enhancer outside of its use for sleep-deprived populations.

A 2020 review reported that modafinil has a modest effect on memory updating, but the effect is small and may not accurately reflect the perception that it is useful as a cognitive enhancer, as there is insufficient evidence to support such a claim.[247]

Post-anesthesia sedation

General anesthesia is required for many surgeries, but may cause lingering fatigue, sedation, and/or drowsiness after surgery that lasts for hours to days.[248] [249] In outpatient surgery the sedation, fatigue, and occasional dizziness is problematic.[250] [251] Modafinil was tested as a potential remedy to alleviate these symptoms. For example, it was expected that modafinil would help people recover quicker from general anesthesia after a short surgery,[236] but the results were uncertain and the inconclusive studies could not reliably verify the expectation.[252] The use of modafinil to relieve post-anesthesia sedation is investigational.[236]

Postural orthostatic tachycardia syndrome

Caution should be exercised in people who have narcolepsy in comorbidity with postural orthostatic tachycardia syndrome (POTS).[253]

Inflammation

A possible link between inflammatory processes and depressive disorders[254] has stimulated preliminary research on modafinil for its potential anti-inflammatory effects.[255]

Notes and References

  1. Web site: TGA eBS - Product and Consumer Medicine Information Licence . February 28, 2024 . February 28, 2024 . https://web.archive.org/web/20240228085348/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2017-PI-01898-1 . live .
  2. Web site: Brazilian Health Regulatory Agency . March 31, 2023 . RDC Nº 784 – Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial . Collegiate Board Resolution No. 784 – Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control. live . https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 . August 3, 2023 . August 3, 2023 . . pt-BR . April 4, 2023.
  3. Web site: Modafinil Product information . Health Canada . April 25, 2012 . June 10, 2022 . June 10, 2022 . https://web.archive.org/web/20220610220622/https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=63139 . live .
  4. Web site: Modafinil Provigil 100 mg Tablets – Summary of Product Characteristics (SMPC) – (Emc) . emc . June 9, 2021 . December 1, 2023 . December 2, 2023 . https://web.archive.org/web/20231202185852/https://www.medicines.org.uk/emc/product/5412/smpc . live .
  5. Web site: Provigil- modafinil tablet . DailyMed . November 30, 2018 . June 10, 2022 . June 10, 2022 . https://web.archive.org/web/20220610220626/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e16c26ad-7bc2-d155-3a5d-da83ad6492c8 . live .
  6. Robertson P, DeCory HH, Madan A, Parkinson A . In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil . Drug Metabolism and Disposition . 28 . 6 . 664–671 . June 2000 . 10820139 .
  7. Robertson P, Hellriegel ET . Clinical pharmacokinetic profile of modafinil . Clinical Pharmacokinetics . 42 . 2 . 123–137 . 2003 . 12537513 . 10.2165/00003088-200342020-00002 . 1266677 .
  8. Web site: Modafinil Monograph for Professionals . Drugs.com . American Society of Health-System Pharmacists . September 23, 2023 . February 3, 2024 . March 30, 2019 . https://web.archive.org/web/20190330181813/https://www.drugs.com/monograph/modafinil.html . live .
  9. Web site: Modafinil. MedlinePlus. February 15, 2016. February 3, 2024. US National Library of Medicine. December 7, 2023. https://web.archive.org/web/20231207203943/https://medlineplus.gov/druginfo/meds/a602016.html. live.
  10. Kaplan S, Braverman DL, Frishman I, Bartov N . Pregnancy and Fetal Outcomes Following Exposure to Modafinil and Armodafinil During Pregnancy . JAMA Internal Medicine . 181 . 2 . 275–277 . February 2021 . 33074297 . 7573789 . 10.1001/jamainternmed.2020.4009 .
  11. Maski K, Trotti LM, Kotagal S, Robert Auger R, Rowley JA, Hashmi SD, Watson NF . Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline . Journal of Clinical Sleep Medicine . 17 . 9 . 1881–1893 . September 2021 . 34743789 . 8636351 . 10.5664/jcsm.9328 .
  12. Kim D . Practical use and risk of modafinil, a novel waking drug . Environmental Health and Toxicology . 27 . e2012007 . 2012 . 22375280 . 3286657 . 10.5620/eht.2012.27.e2012007 .
  13. Tanda G, Hersey M, Hempel B, Xi ZX, Newman AH . Modafinil and its structural analogs as atypical dopamine uptake inhibitors and potential medications for psychostimulant use disorder . Current Opinion in Pharmacology . 56 . 13–21 . February 2021 . 32927246 . 8247144 . 10.1016/j.coph.2020.07.007 .
  14. Kakehi S, Tompkins DM . A Review of Pharmacologic Neurostimulant Use During Rehabilitation and Recovery After Brain Injury . Ann Pharmacother . 55 . 10 . 1254–1266 . October 2021 . 33435717 . 10.1177/1060028020983607 . 231593912 .
  15. Barateau L, Pizza F, Plazzi G, Dauvilliers Y . Narcolepsy . Journal of Sleep Research . 31 . 4 . e13631 . August 2022 . 35624073 . 10.1111/jsr.13631 . 251107306 .
  16. Anderson D . Narcolepsy: A clinical review . JAAPA . 34 . 6 . 20–25 . June 2021 . 34031309 . 10.1097/01.JAA.0000750944.46705.36 . 241205299 . free . doi .
  17. Kallweit U, Bassetti CL . Pharmacological management of narcolepsy with and without cataplexy . Expert Opin Pharmacother . 18 . 8 . 809–817 . June 2017 . 28443381 . 10.1080/14656566.2017.1323877 . 1906751 .
  18. Hashemian SM, Farhadi T . A review on modafinil: the characteristics, function, and use in critical care . Journal of Drug Assessment . 9 . 1 . 82–86 . 2020 . 32341841 . 7170336 . 10.1080/21556660.2020.1745209 .
  19. Morgenthaler TI, Lee-Chiong T, Alessi C, Friedman L, Aurora RN, Boehlecke B, Brown T, Chesson AL, Kapur V, Maganti R, Owens J, Pancer J, Swick TJ, Zak R . Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. An American Academy of Sleep Medicine report . Sleep . 30 . 11 . 1445–1459 . November 2007 . 18041479 . 2082098 . 10.1093/sleep/30.11.1445 .
  20. Web site: Modafinil (Provigil): Now restricted to narcolepsy . . December 2, 2023 . December 15, 2023 . https://web.archive.org/web/20231215212604/https://www.gov.uk/drug-safety-update/modafinil-provigil-now-restricted-to-narcolepsy . live .
  21. Web site: Modafinil: Restricted use recommended . . December 2, 2023 . December 2, 2023 . https://web.archive.org/web/20231202141511/https://www.gov.uk/drug-safety-update/modafinil-restricted-use-recommended . live .
  22. Arnulf I, Thomas R, Roy A, Dauvilliers Y . Update on the treatment of idiopathic hypersomnia: Progress, challenges, and expert opinion . Sleep Medicine Reviews . 69 . 101766 . June 2023 . 36921459 . 10.1016/j.smrv.2023.101766 . 257214950 . free . doi . July 13, 2024 . August 6, 2024 . https://web.archive.org/web/20240806000406/https://hal.science/hal-04588723/document . live .
  23. Winter Y, Lang C, Kallweit U, Apel D, Fleischer V, Ellwardt E, Groppa S . Pitolisant-supported bridging during drug holidays to deal with tolerance to modafinil in patients with narcolepsy . Sleep Med . 112 . 116–121 . December 2023 . 37839272 . 10.1016/j.sleep.2023.10.005 . free .
  24. Web site: Multiple sclerosis in adults: Management, Guidance . The National Institute for Health and Care Excellence (NICE) . June 22, 2022 . September 5, 2022 . September 5, 2022 . https://web.archive.org/web/20220905191147/https://www.nice.org.uk/guidance/ng220 . live .
  25. Web site: Provigil . National Multiple Sclerosis Society . September 6, 2022 . September 5, 2022 . https://web.archive.org/web/20220905191147/https://www.nationalmssociety.org/Treating-MS/Medications/Provigil . live .
  26. Ayache SS, Serratrice N, Abi Lahoud GN, Chalah MA . Fatigue in Multiple Sclerosis: A Review of the Exploratory and Therapeutic Potential of Non-Invasive Brain Stimulation . Front Neurol . 13 . 813965 . 2022 . 35572947 . 9101483 . 10.3389/fneur.2022.813965 . free .
  27. Oliva Ramirez A, Keenan A, Kalau O, Worthington E, Cohen L, Singh S . Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review . BMC Neurol . 21 . 1 . 468 . December 2021 . 34856949 . 8638268 . 10.1186/s12883-021-02396-1 . free .
  28. Ciancio A, Moretti MC, Natale A, Rodolico A, Signorelli MS, Petralia A, Altamura M, Bellomo A, Zanghì A, D'Amico E, Avolio C, Concerto C . Personality Traits and Fatigue in Multiple Sclerosis: A Narrative Review . Journal of Clinical Medicine . 12 . 13 . 4518 . July 2023 . 37445551 . 10342558 . 10.3390/jcm12134518 . free . doi .
  29. MacAllister WS, Krupp LB . Multiple sclerosis-related fatigue . Physical Medicine and Rehabilitation Clinics of North America . 16 . 2 . 483–502 . May 2005 . 15893683 . 10.1016/j.pmr.2005.01.014 .
  30. Brown JN, Howard CA, Kemp DW . Modafinil for the treatment of multiple sclerosis-related fatigue . The Annals of Pharmacotherapy . 44 . 6 . 1098–1103 . June 2010 . 20442351 . 10.1345/aph.1M705 . 207263842 .
  31. Shangyan H, Kuiqing L, Yumin X, Jie C, Weixiong L . Meta-analysis of the efficacy of modafinil versus placebo in the treatment of multiple sclerosis fatigue . Mult Scler Relat Disord . 19 . 85–89 . January 2018 . 29175676 . 10.1016/j.msard.2017.10.011.
  32. Wilms W, Woźniak-Karczewska M, Corvini PF, Chrzanowski Ł . Nootropic drugs: Methylphenidate, modafinil and piracetam - Population use trends, occurrence in the environment, ecotoxicity and removal methods - A review . Chemosphere . 233 . 771–785 . October 2019 . 31200137 . 10.1016/j.chemosphere.2019.06.016 . 189861826 . 2019Chmsp.233..771W .
  33. Kittel-Schneider S, Quednow BB, Leutritz AL, McNeill RV, Reif A . Parental ADHD in pregnancy and the postpartum period - A systematic review . Neuroscience and Biobehavioral Reviews . 124 . 63–77 . May 2021 . 33516734 . 10.1016/j.neubiorev.2021.01.002 . 231723198 . October 19, 2023 . October 21, 2023 . https://web.archive.org/web/20231021234946/https://www.zora.uzh.ch/id/eprint/198979/1/Kittel-Schneider_et_al_2021.pdf . live .
  34. Weiergräber M, Ehninger D, Broich K . Neuroenhancement and mood enhancement – Physiological and pharmacodynamical background . Medizinische Monatsschrift Fur Pharmazeuten . 40 . 4 . 154–164 . April 2017 . 29952165 .
  35. Stuhec M, Lukić P, Locatelli I . Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis . The Annals of Pharmacotherapy . 53 . 2 . 121–133 . February 2019 . 30117329 . 10.1177/1060028018795703 . 52019992 .
  36. Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A . Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis . The Lancet. Psychiatry . 5 . 9 . 727–738 . September 2018 . 30097390 . 6109107 . 10.1016/S2215-0366(18)30269-4 .
  37. Rodrigues R, Lai MC, Beswick A, Gorman DA, Anagnostou E, Szatmari P, Anderson KK, Ameis SH . Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis . Journal of Child Psychology and Psychiatry, and Allied Disciplines . 62 . 6 . 680–700 . June 2021 . 32845025 . 10.1111/jcpp.13305 . 221329069 .
  38. Turner D . A review of the use of modafinil for attention-deficit hyperactivity disorder . Expert Review of Neurotherapeutics . 6 . 4 . 455–468 . April 2006 . 16623645 . 10.1586/14737175.6.4.455 . 24293088 .
  39. Lindsay SE, Gudelsky GA, Heaton PC . Use of modafinil for the treatment of attention deficit/hyperactivity disorder . The Annals of Pharmacotherapy . 40 . 10 . 1829–1833 . October 2006 . 16954326 . 10.1345/aph.1H024 . 37368284 .
  40. Bond DJ, Hadjipavlou G, Lam RW, McIntyre RS, Beaulieu S, Schaffer A, Weiss M . The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder . Annals of Clinical Psychiatry . 24 . 1 . 23–37 . February 2012 . 22303520 .
  41. Book: Efficacy of Amphetamines, Methylphenidate, and Modafinil in the Treatment of Mental Disorders. 10.1007/978-3-030-62059-2_319. Retz W. NeuroPsychopharmacotherapy . 2022 . 2465–2486 . 978-3-030-62058-5 .
  42. Dell'Osso B, Ketter TA . Use of adjunctive stimulants in adult bipolar depression . Int J Neuropsychopharmacol . 16 . 1 . 55–68 . February 2013 . 22717304 . 10.1017/S1461145712000326 . 2434/265768 . free .
  43. Shen YC . Treatment of acute bipolar depression . Ci Ji Yi Xue Za Zhi . 30 . 3 . 141–147 . 2018 . 30069121 . 6047324 . 10.4103/tcmj.tcmj_71_18 . free .
  44. Nunez NA, Singh B, Romo-Nava F, Joseph B, Veldic M, Cuellar-Barboza A, Cabello Arreola A, Vande Voort JL, Croarkin P, Moore KM, Biernacka J, McElroy SL, Frye MA . Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: A meta-analysis of randomized controlled trials . Bipolar Disorders . 22 . 2 . 109–120 . March 2020 . 31643130 . 10.1111/bdi.12859 . free . doi .
  45. Elsayed OH, Ercis M, Pahwa M, Singh B . Treatment-Resistant Bipolar Depression: Therapeutic Trends, Challenges and Future Directions . Neuropsychiatric Disease and Treatment . 18 . 2927–2943 . 2022 . 36561896 . 9767030 . 10.2147/NDT.S273503 . free . doi .
  46. Miskowiak KW, Obel ZK, Gugliemo R, Bonnin CD, Bowie CR, Balanzá-Martínez V, Burdick KE, Carvalho AF, Dols A, Douglas K, Gallagher P, Kessing LV, Lafer B, Lewandowski KE, López-Jaramillo C, Martinez-Aran A, McIntyre RS, Porter RJ, Purdon SE, Schaffer A, Stokes PR, Sumiyoshi T, Torres IJ, Van Rheenen TE, Yatham LN, Young AH, Vieta E, Hasler G . Efficacy and safety of established and off-label ADHD drug therapies for cognitive impairment or attention-deficit hyperactivity disorder symptoms in bipolar disorder: A systematic review by the ISBD Targeting Cognition Task Force . Bipolar Disord . March 2024 . 26 . 3 . 216–239 . 38433530 . 10.1111/bdi.13414 . free .
  47. Web site: Modafinil in the treatment of selected mental disorders . . February 14, 2024 . February 14, 2024 . https://web.archive.org/web/20240214153327/https://www.proquest.com/openview/017f800499b0259521ea4ef8ccf503a8/1?pq-origsite=gscholar&cbl=5540454 . live .
  48. 10.4088/JCP.19r12767 . The Potential Procognitive Effects of Modafinil in Major Depressive Disorder . 2019 . The Journal of Clinical Psychiatry . 80 . 6 . 31599501 . 204028869 . Vaccarino SR, McInerney SJ, Kennedy SH, Bhat V .
  49. Bartoli F, Cavaleri D, Bachi B, Moretti F, Riboldi I, Crocamo C, Carrà G . Repurposed drugs as adjunctive treatments for mania and bipolar depression: A meta-review and critical appraisal of meta-analyses of randomized placebo-controlled trials . Journal of Psychiatric Research . 143 . 230–238 . November 2021 . 34509090 . 10.1016/j.jpsychires.2021.09.018 . 237485915 .
  50. 10.1080/14656566.2023.2194488 . An update on potential pharmacotherapies for cognitive impairment in bipolar disorder . 2023 . Expert Opinion on Pharmacotherapy . 24 . 5 . 641–654 . 36946229 . 257665446 . Johnson DE, McIntyre RS, Mansur RB, Rosenblat JD .
  51. Salvadore G, Quiroz JA, Machado-Vieira R, Henter ID, Manji HK, Zarate CA . The neurobiology of the switch process in bipolar disorder: a review . The Journal of Clinical Psychiatry . 71 . 11 . 1488–1501 . November 2010 . 20492846 . 3000635 . 10.4088/JCP.09r05259gre .
  52. Perugi G, Vannucchi G, Bedani F, Favaretto E . Use of Stimulants in Bipolar Disorder . Current Psychiatry Reports . 19 . 1 . 7 . January 2017 . 28144880 . 10.1007/s11920-017-0758-x . 2932701 .
  53. Web site: Hughes S. New Scientist. February 1991. Drugged troops could soldier on without sleep. https://web.archive.org/web/20210122134909/https://www.newscientist.com/article/mg12917551-800-drugged-troops-could-soldier-on-without-sleep/. January 22, 2021. live. December 2, 2023.
  54. Van Puyvelde M, Van Cutsem J, Lacroix E, Pattyn N . A State-of-the-Art Review on the Use of Modafinil as a Performance-enhancing Drug in the Context of Military Operationality . Military Medicine . 187 . 1–2 . 52–64 . January 2022 . 34632515 . 10.1093/milmed/usab398 . free . doi .
  55. Brunyé TT, Brou R, Doty TJ. A Review of US Army Research Contributing to Cognitive Enhancement in Military Contexts. J Cogn Enhanc. 4 . 4. 453–468. 2020. 10.1007/s41465-020-00167-3. 256621326 .
  56. Gonzalez J . Go Pills for Black Shoes? . U.S. Naval Institute Proceedings . July 2017 . 143 . 7/1,373 . December 3, 2023 . December 3, 2023 . https://web.archive.org/web/20231203140637/https://www.usni.org/magazines/proceedings/2017/july/go-pills-black-shoes . live .
  57. Caldwell JA, Caldwell JL . Fatigue in military aviation: an overview of US military-approved pharmacological countermeasures . Aviation, Space, and Environmental Medicine . 76 . 7 Suppl . C39–C51 . July 2005 . 16018329 .
  58. News: MoD bought thousands of stay awake pills in advance of war in Iraq . . July 29, 2004 . Sample I, Evans R . December 2, 2023 . December 2, 2023 . https://web.archive.org/web/20231202042216/https://www.theguardian.com/society/2004/jul/29/health.sciencenews . live .
  59. It's Wake-Up Time. Martin R. November 1, 2003. Wired. May 23, 2019. 1059-1028. October 17, 2020. https://web.archive.org/web/20201017212750/https://www.wired.com/2003/11/sleep/. live.
  60. Web site: Air Force Special Operations Command Instruction 48–101 . https://web.archive.org/web/20180410202141/http://static.e-publishing.af.mil/production/1/afsoc/publication/afi11-202v3_afsocsup/afi11-202v3_afsocsup.pdf . April 10, 2018 . (sects. 1.7.4), U.S. Air Force Special Operations Command . November 30, 2012 .
  61. Thirsk R, Kuipers A, Mukai C, Williams D . The space-flight environment: the International Space Station and beyond . CMAJ . 180 . 12 . 1216–1220 . June 2009 . 19487390 . 2691437 . 10.1503/cmaj.081125 .
  62. News: Slotnik DE . Smart drugs . . December 3, 2023 . 0013-0613 . December 3, 2023 . https://web.archive.org/web/20231203141554/https://www.economist.com/leaders/2008/05/22/smart-drugs . live .
  63. News: Slotnik DE . October 11, 2017 . Michel Jouvet, Who Unlocked REM Sleep's Secrets, Dies at 91 . . December 3, 2023 . 0362-4331 . December 3, 2023 . https://web.archive.org/web/20231203143118/https://www.nytimes.com/2017/10/11/obituaries/michel-jouvet-who-unlocked-rem-sleeps-secrets-dies-at-91.html . live .
  64. News: Cadwalladr C. Students used to take drugs to get high. Now they take them to get higher grades. The Guardian. February 14, 2015. January 7, 2017. August 3, 2020. https://web.archive.org/web/20200803132607/https://www.theguardian.com/society/2015/feb/15/students-smart-drugs-higher-grades-adderall-modafinil. live.
  65. News: Cumming E . November 3, 2009 . The drug does work . . December 3, 2023 . 0013-0613 . December 3, 2023 . https://web.archive.org/web/20231203141443/https://www.economist.com/1843/2009/11/03/the-drug-does-work . live .
  66. News: May 30, 2017 . Professors are taking the same 'smart drugs' as students to keep up with workloads . January 17, 2023 . The Independent . December 7, 2022 . https://web.archive.org/web/20221207055128/http://www.independent.co.uk/news/education/education-news/professor-smart-drugs-modafinil-noopept-students-workloads-university-research-teaching-academic-cambridge-a7763041.html . live .
  67. Talbot M. Brain Gain. The New Yorker. April 9, 2017. August 19, 2020. https://web.archive.org/web/20200819222934/https://www.newyorker.com/magazine/2009/04/27/brain-gain. live.
  68. News: Towards immortality . November 16, 2006 . . December 3, 2023 . 0013-0613 . December 3, 2023 . https://web.archive.org/web/20231203142303/https://www.economist.com/news/2006/11/16/towards-immortality . live .
  69. Van Rooyen LR, Gihwala R, Laher AE . Stimulant use among prehospital emergency care personnel in Gauteng Province, South Africa . South African Medical Journal = Suid-Afrikaanse Tydskrif vir Geneeskunde . 111 . 6 . 587–590 . May 2021 . 34382572 . 10.7196/SAMJ.2021.v111i6.15465 . 236402826 . free . doi .
  70. News: Supercharging the brain . . September 18, 2004 . December 3, 2023 . 0013-0613 . December 3, 2023 . https://web.archive.org/web/20231203143124/https://www.economist.com/technology-quarterly/2004/09/18/supercharging-the-brain . live .
  71. Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ . Cognitive enhancing effects of modafinil in healthy volunteers . Psychopharmacology . 165 . 3 . 260–269 . January 2003 . 12417966 . 10.1007/s00213-002-1250-8 .
  72. Keating GM, Raffin MJ . Modafinil: a review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder . CNS Drugs . 19 . 9 . 785–803 . 2005 . 16142993 . 10.2165/00023210-200519090-00005 . 43733424 .
  73. Zamanian MY, Karimvandi MN, Nikbakhtzadeh M, Zahedi E, Bokov DO, Kujawska M, Heidari M, Rahmani MR . Effects of Modafinil (Provigil) on Memory and Learning in Experimental and Clinical Studies: From Molecular Mechanisms to Behaviour Molecular Mechanisms and Behavioural Effects . Current Molecular Pharmacology . 16 . 4 . 507–516 . 2023 . 36056861 . 10.2174/1874467215666220901122824 . 252046371 .
  74. Book: Meulen R, Hall W, Mohammed A . Rethinking Cognitive Enhancement . 2017 . Oxford University Press . 978-0-19-872739-2 . 116 .
  75. Battleday RM, Brem AK . Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review . European Neuropsychopharmacology . 25 . 11 . 1865–1881 . November 2015 . 26381811 . 10.1016/j.euroneuro.2015.07.028 . 23319688 .
  76. Schifano F, Catalani V, Sharif S, Napoletano F, Corkery JM, Arillotta D, Fergus S, Vento A, Guirguis A . Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals . Drugs . 82 . 6 . 633–647 . April 2022 . 35366192 . 10.1007/s40265-022-01701-7 . 2299/25614 . 247860331 . free .
  77. Book: Billiard M, Lubin S . Sleep Medicine . Modafinil: Development and Use of the Compound . Springer New York . New York, NY . 2015 . 10.1007/978-1-4939-2089-1_61 . 541–544. 978-1-4939-2088-4 .
  78. Sleep Medications and Women: a Review of Issues to Consider for Optimizing the Care of Women with Sleep Disorders. Krystal A, Attarian H . December 2016. Current Sleep Medicine Reports. 2. 4. 218–222. 10.1007/s40675-016-0060-1.
  79. Ghaffari N, Robertson PA . Caution in Prescribing Modafinil and Armodafinil to Individuals Who Could Become Pregnant . JAMA Intern Med . 181 . 2 . 277–278 . February 2021 . 33074296 . 10.1001/jamainternmed.2020.4206 . 224780160 .
  80. 10.1001/jama.2020.9840 . Incidence of Malformations After Early Pregnancy Exposure to Modafinil in Sweden and Norway . 2020 . JAMA . 324 . 9 . 895–897 . 32870289 . 7489822 . Cesta CE, Engeland A, Karlsson P, Kieler H, Reutfors J, Furu K .
  81. Web site: Modafinil (Provigil): increased risk of congenital malformations if used during pregnancy. November 16, 2020. GOV.UK. January 13, 2024. January 13, 2024. https://web.archive.org/web/20240113182538/https://www.gov.uk/drug-safety-update/modafinil-provigil-increased-risk-of-congenital-malformations-if-used-during-pregnancy. live.
  82. Web site: The Safety of Stimulant Medication Use in Cardiovascular and Arrhythmia Patients . January 29, 2024 . January 29, 2024 . https://web.archive.org/web/20240129013130/https://www.acc.org/latest-in-cardiology/articles/2015/04/28/10/06/the-safety-of-stimulant-medication-use-in-cardiovascular-and-arrhythmia-patients . live .
  83. Web site: Modafinil: Annex III Summary of Product Characteristics, Labelling and Package Leaflet . European Medicines Agency . January 29, 2024 . January 29, 2024 . https://web.archive.org/web/20240129013129/https://www.ema.europa.eu/en/documents/referral/modafinil-annex-iii-summary-product-characteristics-labeling-or-package-leaflet_en.pdf . live .
  84. Oskooilar N . A case of premature ventricular contractions with modafinil . Am J Psychiatry . 162 . 10 . 1983–4 . October 2005 . 16199853 . 10.1176/appi.ajp.162.10.1983-a .
  85. Taneja I, Diedrich A, Black BK, Byrne DW, Paranjape SY, Robertson D . Modafinil elicits sympathomedullary activation . Hypertension . 45 . 4 . 612–8 . April 2005 . 15753235 . 10.1161/01.HYP.0000158267.66763.63 . 9192971 . 10.1.1.521.5289 .
  86. Hou RH, Freeman C, Langley RW, Szabadi E, Bradshaw CM . Does modafinil activate the locus coeruleus in man? Comparison of modafinil and clonidine on arousal and autonomic functions in human volunteers . Psychopharmacology (Berl) . 181 . 3 . 537–49 . September 2005 . 15983798 . 10.1007/s00213-005-0013-8 . 10265746 .
  87. Web site: Evans K, Tay S . September 2020 . Shared Care Guideline – Modafinil for narcolepsy (adults) and excessive daytime sleepiness in Parkinson's disease . York and Scarborough Medicines Commissioning Committee . January 30, 2024 . January 30, 2024 . https://web.archive.org/web/20240130034658/https://www.yorkandscarboroughformulary.nhs.uk/docs/SC/Modafinil%20shared%20care%20guideline%20v2.pdf . live .
  88. Web site: Miller M . Morgan J . Hull & East Riding Prescribing Committee . Prescribing Framework for Modafinil for Daytime Hypersomnolence and excessive daytime sleepiness in Parkinsons . Northern Lincolnshire, UK . National Health Service . December 2, 2023 . December 2, 2023 . https://web.archive.org/web/20231202001703/https://www.hey.nhs.uk/wp/wp-content/uploads/2021/06/modafanil.pdf . live .
  89. Web site: Modafinil for the treatment of adult patients with excessive sleepiness . November 10, 2022 . National Health Service, UK . December 2, 2023 . December 2, 2023 . https://web.archive.org/web/20231202001703/https://gmmmg.nhs.uk/wp-content/uploads/2022/12/GMMMG-Modafinil-primary-care-info-leaflet_Nov-22-approved.pdf . live .
  90. Book: Bello NT. A worldwide yearly survey of new data in adverse drug reactions. Central Nervous System Stimulants and Drugs That Suppress Appetite. Ray SD. Side Effects of Drugs Annual. Elsevier. 37. 2015. 1–13. 0378-6080. 978-0-444-63525-9. 10.1016/bs.seda.2015.08.004.
  91. Book: Greenblatt K, Adams N . Modafinil . StatPearls . Treasure Island (FL) . StatPearls Publishing . February 2022 . 30285371 . .
  92. Web site: Australian Adverse Drug Reactions Bulletin 2008 . Australian Adverse Drug Reactions Bulletin . December 1, 2008 . July 3, 2020 . https://web.archive.org/web/20200703041749/https://www.tga.gov.au/publication-issue/australian-adverse-drug-reactions-bulletin-vol-27-no-6#a2 . live .
  93. Web site: Provigil . November 1, 2010 . Medication Guide . Cephalon, Inc. . December 31, 2013 . https://web.archive.org/web/20160304035819/http://provigil.com/media/PDFs/medication_guide.pdf . March 4, 2016 . dead .
  94. Book: 31643597. Modafinil . LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].. Bethesda (MD) . National Institute of Diabetes and Digestive and Kidney Diseases . 2012. .
  95. Web site: Modafinil (marketed as Provigil): Serious Skin Reactions . U.S. Food and Drug Administration (FDA) . 2007 . January 15, 2009 . https://web.archive.org/web/20090115021301/http://www.fda.gov/cder/dsn/2007_fall/postmarketing.htm#modafinil . dead .
  96. News: Li TW. Three men hospitalised after taking modafinil or armodafinil to stay awake; drugs were not prescribed. November 6, 2023. The Straits Times. December 3, 2023. December 3, 2023. https://web.archive.org/web/20231203191528/https://www.straitstimes.com/singapore/three-men-hospitalised-after-taking-modafinil-or-armodafinil-to-stay-awake-drugs-were-not-prescribed. live.
  97. Web site: FDA Provigil Drug Safety Data. January 2015. U.S. Food and Drug Administration (FDA) . May 2, 2017. https://web.archive.org/web/20170502094203/https://www.fda.gov/downloads/Drugs/DrugSafety/UCM231722.pdf. live.
  98. Sousa A, Dinis-Oliveira RJ . Article commentary: Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects . Substance Abuse . 41 . 2 . 155–173 . 2020 . 31951804 . 10.1080/08897077.2019.1700584 . 210709160 .
  99. Rugino T . A review of modafinil film-coated tablets for attention-deficit/hyperactivity disorder in children and adolescents . Neuropsychiatric Disease and Treatment . 3 . 3 . 293–301 . June 2007 . 19300563 . 2654790 .
  100. Billiard M, Broughton R . Modafinil: its discovery, the early European and North American experience in the treatment of narcolepsy and idiopathic hypersomnia, and its subsequent use in other medical conditions . Sleep Med . 49 . 69–72 . September 2018 . 30174215 . 10.1016/j.sleep.2018.05.027 . 52143478 .
  101. Book: Sleep in Narcolepsy and the Effects of Modafinil. Billiard M. Dopamine and Sleep . 10.1007/978-3-319-46437-4_11. October 25, 2016. 235–253 . Springer, Cham. 978-3-319-46435-0.
  102. Banerjee D, Vitiello MV, Grunstein RR . Pharmacotherapy for excessive daytime sleepiness . Sleep Med Rev . 8 . 5 . 339–54 . October 2004 . 15336235 . 10.1016/j.smrv.2004.03.002 .
  103. Bassetti CL, Kallweit U, Vignatelli L, Plazzi G, Lecendreux M, Baldin E, Dolenc-Groselj L, Jennum P, Khatami R, Manconi M, Mayer G, Partinen M, Pollmächer T, Reading P, Santamaria J, Sonka K, Dauvilliers Y, Lammers GJ . European guideline and expert statements on the management of narcolepsy in adults and children . Journal of Sleep Research . 30 . 6 . e13387 . December 2021 . 34173288 . 10.1111/jsr.13387 . 235648766 . free . doi . 11380/1251554 . free .
  104. Sharif S, Guirguis A, Fergus S, Schifano F . The Use and Impact of Cognitive Enhancers among University Students: A Systematic Review . Brain Sciences . 11 . 3 . 355 . March 2021 . 33802176 . 8000838 . 10.3390/brainsci11030355 . free . doi .
  105. Web site: 64. 17. Department of Justice. Federal register. 64 FR 4050 - Schedules of Controlled Substances: Placement of Modafinil Into Schedule IV. January 27, 1999. Sapienza F. February 5, 2024. February 5, 2024. https://web.archive.org/web/20240205144036/https://www.govinfo.gov/app/details/FR-1999-01-27/99-1791. live.
  106. Mignot EJ . A practical guide to the therapy of narcolepsy and hypersomnia syndromes . Neurotherapeutics . 9 . 4 . 739–752 . October 2012 . 23065655 . 3480574 . 10.1007/s13311-012-0150-9 .
  107. Warot D, Corruble E, Payan C, Weil JS, Puech AJ. 1993. Subjective effects of modafinil, a new central adrenergic stimulant in healthy volunteers: a comparison with amphetamine, caffeine, and placebo. European Psychiatry . 8. 4. 201–208. 10.1017/S0924933800002923. 151797528 .
  108. de Wit H, Phillips TJ . Do initial responses to drugs predict future use or abuse? . Neurosci Biobehav Rev . 36 . 6 . 1565–76 . July 2012 . 22542906 . 3372699 . 10.1016/j.neubiorev.2012.04.005 .
  109. O'Brien CP, Dackis CA, Kampman K . Does modafinil produce euphoria? . The American Journal of Psychiatry . 163 . 6 . 1109 . June 2006 . 16741217 . 10.1176/ajp.2006.163.6.1109 .
  110. Martins B, Rutland W, De Aquino JP, Kazer BL, Funaro M, Potenza MN, Angarita GA . Helpful or Harmful? The Therapeutic Potential of Medications with Varying Degrees of Abuse Liability in the Treatment of Substance Use Disorders . Curr Addict Rep . 9 . 4 . 647–659 . 2022 . 35990796 . 9376579 . 10.1007/s40429-022-00432-9 .
  111. Web site: . Yellow List: List of Narcotic Drugs Under International Control . In accordance with the Single Convention on Narcotic Drugs, 1961 [Protocol of March 25, 1972, amending the Single Convention on Narcotic Drugs, 1961] . July 2020 . 59th . January 12, 2022 . January 16, 2022 . https://web.archive.org/web/20220116102908/https://www.incb.org/incb/en/narcotic-drugs/Yellowlist/yellow-list.html .
  112. Web site: International Narcotics Control Board . Green List: List of Psychotropic Substances Under International Control . In accordance with Convention psychotropic substances of 1971 . July 2020 . 31st . January 12, 2022 . January 18, 2022 . https://web.archive.org/web/20220118201426/https://www.incb.org/incb/en/psychotropics/toolkit.html . live .
  113. Reinert JP, Dunn RL . Management of overdoses of loperamide, gabapentin, and modafinil: a literature review . Expert Review of Clinical Pharmacology . 12 . 9 . 901–908 . September 2019 . 31422705 . 10.1080/17512433.2019.1657830 . 201063075 .
  114. Prince V, Philippidou M, Walsh S, Creamer D . Stevens-Johnson syndrome induced by modafinil . Clinical and Experimental Dermatology . 43 . 2 . 191–192 . March 2018 . 29028129 . 10.1111/ced.13282 . 204987385 .
  115. 10.1007/s40278-018-42202-6 . Modafinil overdose . Reactions Weekly . 2018 . 1690 . 136 . 195079873 .
  116. Adrafinil: A Novel Vigilance Promoting Agent. Milgram NW, Callahan H, Siwak C. September 1999. CNS Drug Reviews. 5. 3. 193–212. 10.1111/j.1527-3458.1999.tb00100.x .
  117. Nazarian S, Abdolmaleki Z, Torfeh A, Shirazi Beheshtiha SH . Mesenchymal stem cells with modafinil (gold nanoparticles) significantly improves neurological deficits in rats after middle cerebral artery occlusion . Experimental Brain Research . 238 . 11 . 2589–2601 . November 2020 . 32886135 . 10.1007/s00221-020-05913-9 . 221495887 .
  118. Spiller HA, Hays HL, Aleguas A . Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management . CNS Drugs . 27 . 7 . 531–543 . July 2013 . 23757186 . 10.1007/s40263-013-0084-8 .
  119. 10.1007/s40278-018-52897-7. Modafinil overdose/misuse/abuse. Reactions Weekly. 1723. 215. 2018. 195081462 .
  120. Spiller HA, Borys D, Griffith JR, Klein-Schwartz W, Aleguas A, Sollee D, Anderson DA, Sawyer TS . Toxicity from modafinil ingestion . Clinical Toxicology . 47 . 2 . 153–156 . February 2009 . 18787992 . 10.1080/15563650802175595 . 12421545 .
  121. Web site: Modafinil Interactions . Drugs.com . January 10, 2024 . February 5, 2024 . December 15, 2023 . https://web.archive.org/web/20231215212735/https://www.drugs.com/drug-interactions/modafinil.html . live .
  122. Web site: Drug Development and Drug Interactions | Table of Substrates, Inhibitors and Inducers . U.S. Food and Drug Administration (FDA) . May 26, 2021 . April 8, 2022 . November 4, 2020 . https://web.archive.org/web/20201104173036/https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers . live .
  123. Web site: Cytochrome P450 3A (including 3A4) inhibitors and inducers . UpToDate . April 8, 2022 . April 8, 2022 . https://web.archive.org/web/20220408220537/https://www.uptodate.com/contents/image?imageKey=CARD%2F76992 . live .
  124. Robertson P, Hellriegel ET, Arora S, Nelson M . Effect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers . Journal of Clinical Pharmacology . 42 . 2 . 205–214 . February 2002 . 11831544 . 10.1177/00912700222011120 . 29223738 .
  125. Zhu HJ, Wang JS, Donovan JL, Jiang Y, Gibson BB, DeVane CL, Markowitz JS . Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein . European Journal of Pharmacology . 578 . 2–3 . 148–158 . January 2008 . 17963743 . 2659508 . 10.1016/j.ejphar.2007.09.035 .
  126. Web site: Modafinil drug interactions . Drugs.com . May 3, 2021 . May 3, 2021 . https://web.archive.org/web/20210503184406/https://www.drugs.com/drug-interactions/modafinil-index.html . live .
  127. Web site: Modafinil . Medline Plus . U.S. National Library of Medicine . July 1, 2005 . July 21, 2007 . https://web.archive.org/web/20070610045952/http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a602016.html . June 10, 2007.
  128. Minzenberg MJ, Carter CS . Modafinil: a review of neurochemical actions and effects on cognition . Neuropsychopharmacology . 33 . 7 . 1477–1502 . June 2008 . 17712350 . 10.1038/sj.npp.1301534 . Springer Science and Business Media LLC . 13752498 . free . doi .
  129. Samuels ER, Hou RH, Langley RW, Szabadi E, Bradshaw CM . Comparison of pramipexole and modafinil on arousal, autonomic, and endocrine functions in healthy volunteers . Journal of Psychopharmacology . 20 . 6 . 756–770 . November 2006 . 16401653 . 10.1177/0269881106060770 . SAGE Publications . 8033437 .
  130. Niwa T, Murayama N, Imagawa Y, Yamazaki H . Regioselective hydroxylation of steroid hormones by human cytochromes P450 . Drug Metabolism Reviews . 47 . 2 . 89–110 . May 2015 . 25678418 . 10.3109/03602532.2015.1011658 . Informa UK Limited . 5791536 .
  131. Aquinos BM, García Arabehety J, Canteros TM, de Miguel V, Scibona P, Fainstein-Day P . [Adrenal crisis associated with modafinil use] . es . Medicina . 81 . 5 . 846–849 . 2021 . 34633961 .
  132. Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V, Prisinzano TE, Baumann MH . Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil . The Journal of Pharmacology and Experimental Therapeutics . 329 . 2 . 738–746 . May 2009 . 19197004 . 2672878 . 10.1124/jpet.108.146142 . Bryan Roth .
  133. Krief S, Berrebi-Bertrand I, Nagmar I, Giret M, Belliard S, Perrin D, Uguen M, Robert P, Lecomte JM, Schwartz JC, Finance O, Ligneau X . Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol . Pharmacology Research & Perspectives . 9 . 5 . e00855 . October 2021 . 34423920 . 8381683 . 10.1002/prp2.855 .
  134. Murillo-Rodríguez E, Barciela Veras A, Barbosa Rocha N, Budde H, Machado S . An Overview of the Clinical Uses, Pharmacology, and Safety of Modafinil . ACS Chemical Neuroscience . 9 . 2 . 151–158 . February 2018 . 29115823 . 10.1021/acschemneuro.7b00374 .
  135. Loland CJ, Mereu M, Okunola OM, Cao J, Prisinzano TE, Mazier S, Kopajtic T, Shi L, Katz JL, Tanda G, Newman AH . R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse . Biological Psychiatry . 72 . 5 . 405–413 . September 2012 . 22537794 . 3413742 . 10.1016/j.biopsych.2012.03.022 .
  136. Seeman P, Guan HC, Hirbec H . Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil . Synapse . 63 . 8 . 698–704 . August 2009 . 19391150 . 10.1002/syn.20647 . 17758902 .
  137. Thorpy MJ, Bogan RK . Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications . Sleep Medicine . 68 . 97–109 . April 2020 . 32032921 . 10.1016/j.sleep.2019.09.001 . 203405397 .
  138. Book: Stahl SM . Prescriber's Guide: Stahl's Essential Psychopharmacology . March 2017 . Cambridge University Press . Cambridge, United Kingdom . 978-1-108-22874-9 . 491–495 . 6th . Modafinil .
  139. Gerrard P, Malcolm R . Mechanisms of modafinil: A review of current research . Neuropsychiatric Disease and Treatment . 3 . 3 . 349–364 . June 2007 . 19300566 . 2654794 .
  140. Book: Lazarus M, Chen JF, Huang ZL, Urade Y, Fredholm BB . Adenosine and Sleep . Handbook of Experimental Pharmacology . 253 . 359–381 . 2019 . 28646346 . 10.1007/164_2017_36 . 978-3-030-11270-7 .
  141. Book: Gilman A, Goodman LS, Hardman JG, Limbird LE . Goodman & Gilman's the pharmacological basis of therapeutics . McGraw-Hill . New York . 2001 . 1984 . 978-0-07-135469-1 .
  142. Ramachandra B . A Critical Review of Properties of Modafinil and Analytical, Bioanalytical Methods for its Determination . Critical Reviews in Analytical Chemistry . 46 . 6 . 482–489 . November 2016 . 26908128 . 10.1080/10408347.2016.1153948 . 34069997 .
  143. Chatterjie N, Stables JP, Wang H, Alexander GJ . Anti-narcoleptic agent modafinil and its sulfone: a novel facile synthesis and potential anti-epileptic activity . Neurochemical Research . 29 . 8 . 1481–1486 . August 2004 . 15260124 . 10.1023/b:nere.0000029559.20581.1a . 956077 .
  144. Bogan RK . Armodafinil in the treatment of excessive sleepiness . Expert Opinion on Pharmacotherapy . 11 . 6 . 993–1002 . April 2010 . 20307223 . 3630938 . 10.1517/14656561003705738 .
  145. Analytical characteristics and identification of modafinil and adrafinil in the objects of examination. Polyakov YS, Mikhniuk ON, Hilkevich TY, Chevtchouk TA, Yurchenko RA, Vinarskiy VA. State Institute for Advanced Training and Retraining of Customs Authorities of the Republic of Belarus. 2413-6158. Судебная экспертиза Беларуси. 2018. February 6, 2024. September 28, 2020. https://web.archive.org/web/20200928001949/https://www.elibrary.ru/item.asp?id=36403188. live.
  146. Wong YN, King SP, Laughton WB, McCormick GC, Grebow PE . Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers . Journal of Clinical Pharmacology . 38 . 3 . 276–282 . March 1998 . 9549666 . 10.1002/j.1552-4604.1998.tb04425.x . 26877375 .
  147. Book: Baselt RC . Disposition of Toxic Drugs and Chemicals in Man . Biomedical Publications . Foster City, CA . 2008 . 978-0-9626523-7-0 . 1152–1153.
  148. Spratley TK, Hayes PA, Geer LC, Cooper SD, McKibben TD . Analytical Profiles for Five "Designer" Tryptamines . Microgram Journal . 3 . 1–2 . 54–68 . 2005 . PDF . December 18, 2015 . August 2, 2020 . https://web.archive.org/web/20200802180946/https://www.erowid.org/library/periodicals/microgram/microgram_journal_2005-1.pdf#page=54 . live .
  149. Web site: Modafinil reaction with the Froehde reagent and others . Reagent Tests UK . December 13, 2015 . December 18, 2015 . August 3, 2020 . https://web.archive.org/web/20200803124145/https://www.reagent-tests.uk/blog/modafinil-reaction-with-the-froehde-reagent-and-others/ . live .
  150. De Risi C, Ferraro L, Pollini GP, Tanganelli S, Valente F, Veronese AC . Efficient synthesis and biological evaluation of two modafinil analogues . Bioorganic & Medicinal Chemistry . 16 . 23 . 9904–9910 . December 2008 . 18954992 . 10.1016/j.bmc.2008.10.027 .
  151. Okunola-Bakare OM, Cao J, Kopajtic T, Katz JL, Loland CJ, Shi L, Newman AH . Elucidation of structural elements for selectivity across monoamine transporters: novel 2-[(diphenylmethyl)sulfinyl]acetamide (modafinil) analogues . Journal of Medicinal Chemistry . 57 . 3 . 1000–1013 . February 2014 . 24494745 . 3954497 . 10.1021/jm401754x .
  152. Napoletano F, Schifano F, Corkery JM, Guirguis A, Arillotta D, Zangani C, Vento A . The Psychonauts' World of Cognitive Enhancers . Frontiers in Psychiatry . 11 . 546796 . 2020 . 33024436 . 7516264 . 10.3389/fpsyt.2020.546796 . free . doi .
  153. Ballas CA, Kim D, Baldassano CF, Hoeh N . Modafinil: past, present and future . Expert Review of Neurotherapeutics . 2 . 4 . 449–457 . July 2002 . 19810941 . 10.1586/14737175.2.4.449 . 32939239 .
  154. Web site: Adrafinil . The Governors of the University of Alberta . May 14, 2021 . May 14, 2021 . May 16, 2021 . https://web.archive.org/web/20210516092402/https://go.drugbank.com/drugs/DB08925 . live .
  155. Web site: Drug Approval Package: Provigil (Modafinil) NDA# 20717 . U.S. Food and Drug Administration (FDA) . September 10, 2001 . March 1, 2024 . March 1, 2024 . https://web.archive.org/web/20240301182513/https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020717A_Provigil.cfm . live .
  156. Kesselheim AS, Myers JA, Solomon DH, Winkelmayer WC, Levin R, Avorn J . The prevalence and cost of unapproved uses of top-selling orphan drugs . PLOS ONE . 7 . 2 . e31894 . February 2012 . 22363762 . 3283698 . 10.1371/journal.pone.0031894 . Alessi-Severini S . free . doi . 2012PLoSO...731894K .
  157. Web site: Cephalon: Modafinil – Pharmaceutical industry news . October 8, 1995 . The Pharma Letter . November 15, 2023 . November 15, 2023 . https://web.archive.org/web/20231115191229/https://www.thepharmaletter.com/article/cephalon-modafinil . live .
  158. Gellad WF, Choi P, Mizah M, Good CB, Kesselheim AS . Assessing the chiral switch: approval and use of single-enantiomer drugs, 2001 to 2011 . The American Journal of Managed Care . 20 . 3 . e90–e97 . March 2014 . 24773330 .
  159. Web site: Generic Provigil Availability . . November 2023 . November 15, 2023 . November 15, 2023 . https://web.archive.org/web/20231115191917/https://www.drugs.com/availability/generic-provigil.html . live .
  160. Web site: Product monograph including patient medication information Alertec modafinil tablets, 100 mg, oral mfr. std. central nervous system stimulant . February 28, 2024 . February 21, 2024 . https://web.archive.org/web/20240221143222/https://pdf.hres.ca/dpd_pm/00071543.PDF . live .
  161. Web site: Modafinil . European Medicines Agency . November 18, 2010 . February 28, 2024 . January 20, 2024 . https://web.archive.org/web/20240120112003/https://www.ema.europa.eu/en/medicines/human/referrals/modafinil . live .
  162. Web site: Poisons Standard March 2018 . February 28, 2018 . January 20, 2019 . Legislation.gov.au . August 7, 2020 . https://web.archive.org/web/20200807113733/https://www.legislation.gov.au/Details/F2018L00168 . live .
  163. News: March 26, 2005 . Regulations Amending the Food and Drug Regulations (1184 — Modafinil) . . 140 . 20 . https://web.archive.org/web/20110706181716/http://gazette.gc.ca/archives/p1/2005/2005-03-26/html/reg5-eng.html . July 6, 2011.
  164. Web site: Guidance Document: Determining Prescription Status for Human and Veterinary Drugs. Health. Canada. May 29, 2013. www.canada.ca. February 8, 2024. February 8, 2024. https://web.archive.org/web/20240208124250/https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/guidance-document.html. live.
  165. Web site: The Prescription Drug List. Health. Canada. May 29, 2013. www.canada.ca. February 8, 2024. June 28, 2023. https://web.archive.org/web/20230628231029/https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list.html. live.
  166. Web site: Questions and Answers - Prescription Drug List. Health. Canada. May 30, 2013. www.canada.ca. February 8, 2024. February 8, 2024. https://web.archive.org/web/20240208124251/https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/questions-answers.html. live.
  167. Web site: Bringing health products into Canada for personal use (GUI-0116) . December 23, 2020 . January 29, 2024 . January 29, 2024 . https://web.archive.org/web/20240129173522/https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/importation-exportation/personal-use-health-products-guidance/document.html . live .
  168. Web site: 食品药品监管总局 公安部 国家卫生计生委关于公布麻醉药品和精神药品品种目录的通知 . Notice from the Food and Drug Administration, the Ministry of Public Security, and the National Health and Family Planning Commission on publishing the catalog of narcotic drugs and psychotropic drugs . zh . China Food and Drug Administration. https://web.archive.org/web/20181205061404/http://samr.cfda.gov.cn/WS01/CL0844/94735.html. December 5, 2018. dead.
  169. Web site: 处方管理办法(原卫生部令第53号). Prescription Management Measures (Former Ministry of Health Order No. 53) . 中国政府网 (China Government Network) . zh. February 8, 2019. February 8, 2020. https://web.archive.org/web/20200208155424/http://www.gov.cn/flfg/2007-03/13/content_549406.htm. live.
  170. Web site: Bekendtgørelse om euforiserende stoffer . June 23, 2020 . Retsinformation.dk . da . Narcotics act . October 7, 2020 . November 28, 2020 . https://web.archive.org/web/20201128175558/https://www.retsinformation.dk/eli/lta/2020/950 . live .
  171. Web site: Are you bringing medicine into Denmark? . August 13, 2018 . February 5, 2024 . Danish Medicines Agency . January 26, 2024 . https://web.archive.org/web/20240126183328/https://laegemiddelstyrelsen.dk/en/pharmacies/medicines-imported-from-abroad/medicines-for-human-use/are-you-bringing-medicine-into-denmark/ . live .
  172. Web site: Medicines imported from abroad . March 16, 2022 . February 5, 2024 . Danish Medicines Agency . January 26, 2024 . https://web.archive.org/web/20240126183315/https://laegemiddelstyrelsen.dk/en/pharmacies/medicines-imported-from-abroad/ . live .
  173. Web site: BEK nr 557 af 31/05/2011, Indenrigs- og Sundhedsministeriet. May 31, 2011. February 5, 2024. Civilstyrelsen. January 26, 2024. https://web.archive.org/web/20240126183312/https://www.retsinformation.dk/eli/lta/2011/557. live.
  174. Web site: Lääkealan turvallisuus- ja kehittämiskeskuksen päätöslääkeluettelosta. 2009. Finlex.fi. January 3, 2017. August 23, 2020. https://web.archive.org/web/20200823111409/https://finlex.fi/fi/laki/alkup/2009/20091095. live.
  175. Web site: Prohibited goods. Finnish Customs. February 5, 2024. January 26, 2024. https://web.archive.org/web/20240126183313/https://tulli.fi/en/private-persons/ordering-goods-online/prohibited-goods. live.
  176. Web site: Modafinil. September 19, 2019. February 5, 2024. ((Dopinglinkki)). A-klinikkasäätiö. January 26, 2024. https://web.archive.org/web/20240126183315/https://dopinglinkki.fi/en/info-bank/doping-substances/modafinil/. live.
  177. Web site: Hotărâre Nr. 79 din 23-01-2006 privind aprobarea Listei substanţelor stupefiante, psihotrope şi a plantelor care conţin astfel de substanţe depistate în trafic ilicit, precum şi cantităţile acestora . Decision No. 79 of 01-23-2006 regarding the approval of the List of narcotic, psychotropic substances and plants containing such substances detected in illicit traffic, as well as their quantities . Romanian . Moldavian Ministry of Justice . January 23, 2006 . February 5, 2024 . April 3, 2023 . https://web.archive.org/web/20230403194451/https://www.legis.md/cautare/getResults?doc_id=103676&lang=ro . live .
  178. Web site: Serviciul Vamal al Republicii Moldova – E bine să știm! . Customs Service of the Republic of Moldova - Good to know! . Romanian . Customs Service of the Republic of Moldova . September 4, 2023 . September 4, 2023 . https://web.archive.org/web/20230904105420/https://customs.gov.md/ro/articles/e-bine-sa-stim-1369-ro . live .
  179. Web site: June 30, 2007. curentul.md. Parfeni C. Substanțe psihotrope și un pumnal militar au fost depistate de vameși în coletele poștale. January 29, 2024. January 29, 2024. https://web.archive.org/web/20240129202533/http://curentul.md/stiri/substante-psihotrope-si-un-pumnal-militar-au-fost-depistate-de-vamesi-in-coletele-postale.html. live.
  180. Web site: noi.md. June 30, 2017. Centrul de Sănătate din Edineţ va fi eficientizat energetic. January 29, 2024. January 29, 2024. https://web.archive.org/web/20240129202534/https://noi.md/md/news_id/231399. live.
  181. Web site: LISTA INTERZISĂ - 2018 . Forbidden List - 2018 . AGENȚIA NAȚIONALĂ ANTI-DOPING . National Anti-Doping Agency . Romanian . February 24, 2021 . https://web.archive.org/web/20210224105716/http://anad.gov.ro/web/wp-content/uploads/2017/10/LISTA-2018-web.pdf . dead .
  182. Web site: LEGE 219 26/07/2021 . Law 219 26/07/2021 - . Portal Legislativ . Romanian Legislative Portal. October 16, 2022 . October 16, 2022 . https://web.archive.org/web/20221016104753/https://legislatie.just.ro/Public/DetaliiDocumentAfis/245003 . live . Romanian .
  183. Web site: Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika . The Swedish Medicines Agency's regulations (LVFS 2011: 10) on lists of drugs . sv . https://web.archive.org/web/20190807175859/https://lakemedelsverket.se/upload/lvfs/konsoliderade/LVFS_2011_10_konsoliderad_tom_HSLF-FS_2019_7.pdf . August 7, 2019 . dead .
  184. Web site: MHRA license for Modafinil in UK. MHRA. April 3, 2013. MHRA. London. April 3, 2013. January 22, 2016. https://web.archive.org/web/20160122195257/http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con273748.pdf. live.
  185. Web site: Estupefacientes y Psicotrópicos . Narcotic Drugs and Psychotropic Substances . es . Federal Commission for Protection against Health Risks . https://web.archive.org/web/20070713135452/http://www.cofepris.gob.mx/pyp/estpsic/es.htm . July 13, 2007.
  186. Web site: List of psychotropics. May 24, 2019. July 11, 2019. https://web.archive.org/web/20190711014332/http://www.ncd.mhlw.go.jp/img/en/total.pdf. dead . Narcotics Control Department .
  187. Web site: モダフィニルの向精神薬への指定 . Designation as a psychotropic drug of Modafinyl . Japanese . January 17, 2017 . https://web.archive.org/web/20150515002556/http://www.fukushihoken.metro.tokyo.jp/kenkou/iyaku/sonota/shitei_m/moda.html . May 15, 2015 . dead .
  188. Web site: 医疗用医薬品の添付文书情报-モディオダール锭100mg . Attachment of drugs for doctors-Modio Dal 100mg . 独立行政法人 医薬品医疗机器総合机 . Pharmaceuticals and Medical Devices Agency . ja. https://web.archive.org/web/20190209124042/http://www.info.pmda.go.jp/go/pack/1179047F1022_2_15/. February 9, 2019. dead.
  189. Web site: モダフィニル密輸で逮捕された歯科医師, ダイエットに使用と供述(報道). Dentist who was arrested for Modafinyl smuggling, usage and confidence (report) . ja . Medicallaw.exblog.jp. January 20, 2019. https://web.archive.org/web/20190121010916/https://medicallaw.exblog.jp/20422896/. January 21, 2019. dead.
  190. Web site: 向精神薬をインドから密輸入した男を逮捕 . Arrested a man who imported psychotropic drugs from India . ja . Hayabusa3.5ch.net . January 20, 2019. January 21, 2019. https://web.archive.org/web/20190121064119/https://hayabusa3.5ch.net/test/read.cgi/news/1391949369/ . live.
  191. Web site: Decree of the Government of the Russian Federation of 06.30.1998 N 681 (as amended on 02.26.2013) "On approval of the list of narcotic drugs, psychotropic substances and their precursors subject to control in the Russian Federation" . base.consultant.ru . PDF . January 3, 2017 . August 28, 2021 . https://web.archive.org/web/20210828174157/http://www.consultant.ru/cons/cgi/online.cgi?req=doc&base=LAW&n=142882&fld=134&dst=4294967295&rnd=0.8965571122244&from=141820-563 . live . Russian .
  192. Web site: Россия начнет производить новый стимулятор на базе модафинила . Russia will begin to produce a new stimulator based on modafinil . ru . December 8, 2023 . medvestnik.ru . December 8, 2023 . https://web.archive.org/web/20231208054906/https://medvestnik.ru/content/news/Rossiya-gotovitsya-proizvodit-novyi-stimulyator-na-baze-modafinila.html . live .
  193. Web site: February 19, 2020 . В Петербурге завели дело из-за полученных по почте таблеток от сонливости . In St. Petersburg, a case was started because of the pills received by mail from drowsiness . ru . December 8, 2023 . РБК (RBC) . December 8, 2023 . https://web.archive.org/web/20231208054905/https://www.rbc.ru/society/19/02/2020/5e4d28499a79473eeeac6613 . live .
  194. Web site: October 11, 2023 . "Вместо лечения — тюрьма". Россияне с редкими болезнями оказались в ловушке . "Instead of treatment - a prison." Russians with rare diseases were trapped . December 8, 2023 . РИА Новости (Ria News) . ru . December 8, 2023 . https://web.archive.org/web/20231208054905/https://ria.ru/20231011/son-1901816843.html . live .
  195. Web site: GENERAL REGULATIONS MADE IN TERMS OF THE MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965, AS AMENDED Government Notice R510 in Government Gazette 24727 dated 10 April 2003. 22A/16/b; states that although import and export is restricted, possession is not illegal providing that a prescription is present.. SA Government. April 10, 2003. SAFLII. Pretoria. https://web.archive.org/web/20160422183746/http://saflii.org/za/legis/consol_reg/marsa101o1965rangnr510723.pdf. April 22, 2016. dead.
  196. Book: BNF 74 . September 2017 . Pharmaceutical Press . 978-0-85711-298-9 . 468 . 74.
  197. Web site: Is It Illegal to Obtain Controlled Substances From the Internet? . dead . https://web.archive.org/web/20070709032821/http://www.usdoj.gov/dea/illegal_internet.html . July 9, 2007 . July 21, 2007 . United States Drug Enforcement Administration.
  198. Web site: March 24, 1997 . USC 201 Section 1301.26 Exemptions from import or export requirements for personal medical use . dead . https://web.archive.org/web/20070203125143/http://www.deadiversion.usdoj.gov/21cfr/cfr/1301/1301_26.htm . February 3, 2007 . January 10, 2007 . United States Department of Justice.
  199. Web site: Prescription Drug Marketing Act of 1987 (PDMA), PL 100-293 . https://web.archive.org/web/20080223233036/https://www.fda.gov/opacom/laws/pdma.html . February 23, 2008 . U.S. Food and Drug Administration (FDA) .
  200. Web site: Allison J . October 9, 2009 . Class Action Over Cephalon Off-Label Claims Tossed . Law360 . Cephalon executives have repeatedly said that they do not condone off-label use of Provigil, but in 2002 the company was reprimanded by the FDA for distributing marketing materials that presented the drug as a remedy for tiredness, "decreased activity" and other supposed ailments. In 2008, Cephalon paid $425m and pleaded guilty to a federal criminal charge relating to its promotion of off-label uses for Provigil and two other drugs. . January 12, 2022 . April 30, 2022 . https://web.archive.org/web/20220430201243/https://www.law360.com/articles/127434 . live .
  201. Web site: Modafinil – International Brands. Drugs.com. January 8, 2017. July 18, 2020. https://web.archive.org/web/20200718040144/https://www.drugs.com/international/modafinil.html. live.
  202. Denis F. 2021. Smart drugs et nootropiques. Socio-anthropologie. 43. 97–110. 10.4000/socio-anthropologie.8393. 237863162. 1276-8707. free. doi. February 2, 2024. January 8, 2022. https://web.archive.org/web/20220108000038/https://halshs.archives-ouvertes.fr/halshs-03264161/file/DENIS_F%C3%A9lix_2021.pdf. live.
  203. News: Wakefulness Finds a Powerful Ally. O'Connor A. The New York Times. June 29, 2004. December 2, 2023. December 2, 2023. https://web.archive.org/web/20231202005726/https://www.nytimes.com/2004/06/29/health/wakefulness-finds-a-powerful-ally.html. live.
  204. News: European Students' Use of 'Smart Drugs' is Said to Rise . . July 6, 2014 . Petrounin D . December 2, 2023 . December 2, 2023 . https://web.archive.org/web/20231202005728/https://www.nytimes.com/2014/07/07/world/europe/european-students-use-of-smart-drugs-is-said-to-rise.html . live .
  205. News: Europe Fines Drug Companies for Delaying Generics . . June 19, 2013 . Kanter J . December 2, 2023 . December 2, 2023 . https://web.archive.org/web/20231202005731/https://www.nytimes.com/2013/06/20/business/global/eu-fines-drug-companies-for-delaying-generics.html . live .
  206. Web site: Modafinil – Drug Usage Statistics . ClinCalc . October 7, 2022 . June 6, 2023 . https://web.archive.org/web/20230606002027/https://clincalc.com/DrugStats/Drugs/Modafinil . live .
  207. News: "Pay-For-Delay": The EC fines Teva and Cephalon for delaying the market entry of a generic version of Modafinil . Cuatrecasas . November 16, 2023 . November 16, 2023 . https://web.archive.org/web/20231116214034/https://www.cuatrecasas.com/en/global/art/pay-for-delay-ec-fines-teva-cephalon-delaying-entry-generic-version-modafinil-market . live .
  208. 4927855. US.
  209. Cephalon gets six-month Provigil patent extension . Philadelphia Business Journal . March 28, 2006 . July 21, 2007 . August 4, 2008 . https://web.archive.org/web/20080804204005/http://www.bizjournals.com/philadelphia/stories/2006/03/27/daily13.html . live .
  210. Web site: Details for Patent: RE37516 . November 29, 2009 . January 1, 2014 . https://web.archive.org/web/20140101192226/http://www.drugpatentwatch.com/ultimate/preview/patent/index.php?query=RE37516 . live .
  211. Web site: Document 514 :: APOTEX, INC. v. CEPHALON, INC. et al . Pennsylvania Eastern District Court :: US Federal District Courts Cases :: Justia . October 31, 2010 . July 4, 2012 . January 1, 2014 . https://web.archive.org/web/20140101044356/http://law.justia.com/cases/federal/district-courts/pennsylvania/paedce/2:2006cv02768/205626/514 . live .
  212. Court of Appeals, 3rd Circuit. In re: Modafinil Antitrust Litigation. 2016.
  213. Book: World Anti-Doping Agency . The World Anti-Doping Code: International Standard . Prohibited List 2018 . https://www.wada-ama.org/sites/default/files/prohibited_list_2018_en.pdf . September 5, 2017 . January 12, 2022 . July 3, 2021 . https://web.archive.org/web/20210703232308/https://www.wada-ama.org/en/content/what-is-prohibited . live .
  214. Citius, Altius, Fortius—Advanced Mass Spectrometry in Service of Forensic Analysis. Grocholska P, Popiel D, Walter M, Biernat M, Cebrat M, Kuczer M, Modzel M, Bąchor R, Kluczyk A . August 2022 . Chemosensors . 10 . 8 . 324 . 10.3390/chemosensors10080324 . free .
  215. News: Nazzaro MN . August 17, 2013 . Out of Track's Doping Scandal, Redemption and Progress . . December 3, 2023 . 0362-4331 . December 3, 2023 . https://web.archive.org/web/20231203143118/https://www.nytimes.com/2013/08/18/sports/olympics/out-of-a-doping-scandal-redemption-for-Kelli-White-and-progress-for-track.html . live .
  216. News: Clinger given lifetime ban for second doping infraction . Cycling News . August 14, 2011 . October 8, 2014 . October 13, 2014 . https://web.archive.org/web/20141013173114/http://www.cyclingnews.com/news/clinger-given-lifetime-ban-for-second-doping-infraction . live .
  217. News: Taurasi tested positive for modafinil . . December 25, 2010 . December 31, 2013 . October 6, 2014 . https://web.archive.org/web/20141006091440/http://www.washingtonpost.com/wp-dyn/content/article/2010/12/24/AR2010122402993.html . live .
  218. News: British rowers handed two-year bans for taking banned substances. November 23, 2015. The Guardian. December 15, 2016. July 9, 2020. https://web.archive.org/web/20200709214752/https://www.theguardian.com/sport/2015/nov/23/british-rowers-handed-two-year-bans-doping-violations-sybren-hoogland-timothy-grant. live.
  219. Web site: Taurasi: 'I've lost 3 months of my career' . Voepel M . February 18, 2011 . April 11, 2011 . October 6, 2015 . https://web.archive.org/web/20151006020737/http://sports.espn.go.com/wnba/columns/story?columnist=voepel_mechelle&id=6135920 . live .
  220. News: White guilty of doping. September 9, 2003. news.bbc.co.uk. November 15, 2023. November 15, 2023. https://web.archive.org/web/20231115164109/http://news.bbc.co.uk/sport2/hi/athletics/world_athletics_2003/3077070.stm. live.
  221. News: Book alleges Bonds's drug use. CBC News. March 7, 2006. January 27, 2024. January 27, 2024. https://web.archive.org/web/20240127204646/https://www.cbc.ca/sports/baseball/book-alleges-bonds-s-drug-use-1.605000. live.
  222. Web site: Macnaughton O . The rise of smart drugs . March 16, 2016 . Tatler . November 15, 2023 . November 15, 2023 . https://web.archive.org/web/20231115162141/https://www.tatler.com/article/the-rise-of-smart-drugs . live .
  223. Web site: Farrell K . We asked Sussex University if Modafinil is cheating . November 6, 2017 . The Sussex Tab . November 15, 2023 . November 15, 2023 . https://web.archive.org/web/20231115162143/https://thetab.com/uk/sussex/2017/11/06/asked-sussex-university-modafinil-cheating-22575 . live .
  224. 10.1080/17449642.2018.1443050 . Is the use of modafinil, a pharmacological cognitive enhancer, cheating? . 2018 . Porsdam Mann S, de Lora Deltoro P, Cochrane T, Mitchell C . Ethics and Education . 13 . 2 . 251–267 . 149138516 . February 2, 2024 . February 2, 2024 . https://web.archive.org/web/20240202114822/https://philpapers.org/archive/PORITU.pdf . live .
  225. New York Magazine. The Real Limitless Drug Isn't Just for Lifehackers Anymore. March 29, 2013. Robert K . March 16, 2024. December 26, 2023. https://web.archive.org/web/20231226213829/https://nymag.com/news/intelligencer/modafinil-2013-4/. live.
  226. Teodorini RD, Rycroft N, Smith-Spark JH . The off-prescription use of modafinil: An online survey of perceived risks and benefits . PLOS ONE . 15 . 2 . e0227818 . 2020 . 32023288 . 7001904 . 10.1371/journal.pone.0227818 . free . doi . 2020PLoSO..1527818T .
  227. Kornum BR, Knudsen S, Ollila HM, Pizza F, Jennum PJ, Dauvilliers Y, Overeem S . Narcolepsy . Nature Reviews. Disease Primers . 3 . 16100 . February 2017 . 28179647 . 10.1038/nrdp.2016.100 . 266008273 .
  228. Kleeblatt J, Betzler F, Kilarski LL, Bschor T, Köhler S . Efficacy of off-label augmentation in unipolar depression: A systematic review of the evidence . European Neuropsychopharmacology . 27 . 5 . 423–441 . May 2017 . 28318897 . 10.1016/j.euroneuro.2017.03.003 . 3740987 .
  229. McIntyre RS, Lee Y, Zhou AJ, Rosenblat JD, Peters EM, Lam RW, Kennedy SH, Rong C, Jerrell JM . The Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis . Journal of Clinical Psychopharmacology . 37 . 4 . 412–418 . August 2017 . 28590365 . 10.1097/JCP.0000000000000723 . 27622964 .
  230. Bahji A, Mesbah-Oskui L . Comparative efficacy and safety of stimulant-type medications for depression: A systematic review and network meta-analysis . Journal of Affective Disorders . 292 . 416–423 . September 2021 . 34144366 . 10.1016/j.jad.2021.05.119 .
  231. Corp SA, Gitlin MJ, Altshuler LL . A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder . The Journal of Clinical Psychiatry . 75 . 9 . 1010–1018 . September 2014 . 25295426 . 10.4088/JCP.13r08851 .
  232. Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH . Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials . The Journal of Clinical Psychiatry . 74 . 11 . 1101–1107 . November 2013 . 24330897 . 10.4088/JCP.13r08560 .
  233. Malhi GS, Byrow Y, Bassett D, Boyce P, Hopwood M, Lyndon W, Mulder R, Porter R, Singh A, Murray G . Stimulants for depression: On the up and up? . The Australian and New Zealand Journal of Psychiatry . 50 . 3 . 203–207 . March 2016 . 26906078 . 10.1177/0004867416634208 . 45341424 .
  234. Miskowiak KW, Seeberg I, Jensen MB, Balanzá-Martínez V, Del Mar Bonnin C, Bowie CR, Carvalho AF, Dols A, Douglas K, Gallagher P, Hasler G, Lafer B, Lewandowski KE, López-Jaramillo C, Martinez-Aran A, McIntyre RS, Porter RJ, Purdon SE, Schaffer A, Stokes P, Sumiyoshi T, Torres IJ, Van Rheenen TE, Yatham LN, Young AH, Kessing LV, Burdick KE, Vieta E . Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force . Bipolar Disorders . 24 . 4 . 354–374 . June 2022 . 35174594 . 9541874 . 10.1111/bdi.13193 .
  235. Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, Pae CU . Modafinil for the treatment of attention-deficit/hyperactivity disorder: A meta-analysis . Journal of Psychiatric Research . 84 . 292–300 . January 2017 . 27810669 . 10.1016/j.jpsychires.2016.09.034 .
  236. Kumar R . Approved and Investigational Uses of Modafinil . Drugs . 68 . 13 . 1803–1839 . 2008 . 18729534 . 10.2165/00003495-200868130-00003 . 38542387 .
  237. Buoli M, Serati M, Cahn W . Alternative pharmacological strategies for adult ADHD treatment: a systematic review . Expert Review of Neurotherapeutics . 16 . 2 . 131–144 . 2016 . 26693882 . 10.1586/14737175.2016.1135735 . 33004517 .
  238. Kooij JJ, Bijlenga D, Salerno L, Jaeschke R, Bitter I, Balázs J, Thome J, Dom G, Kasper S, Nunes Filipe C, Stes S, Mohr P, Leppämäki S, Casas M, Bobes J, Mccarthy JM, Richarte V, Kjems Philipsen A, Pehlivanidis A, Niemela A, Styr B, Semerci B, Bolea-Alamanac B, Edvinsson D, Baeyens D, Wynchank D, Sobanski E, Philipsen A, McNicholas F, Caci H, Mihailescu I, Manor I, Dobrescu I, Saito T, Krause J, Fayyad J, Ramos-Quiroga JA, Foeken K, Rad F, Adamou M, Ohlmeier M, Fitzgerald M, Gill M, Lensing M, Motavalli Mukaddes N, Brudkiewicz P, Gustafsson P, Tani P, Oswald P, Carpentier PJ, De Rossi P, Delorme R, Markovska Simoska S, Pallanti S, Young S, Bejerot S, Lehtonen T, Kustow J, Müller-Sedgwick U, Hirvikoski T, Pironti V, Ginsberg Y, Félegyházy Z, Garcia-Portilla MP, Asherson P . Updated European Consensus Statement on diagnosis and treatment of adult ADHD . European Psychiatry . 56 . 14–34 . February 2019 . 30453134 . 10.1016/j.eurpsy.2018.11.001 . 53714228 . free . doi . 10651/51910 . free .
  239. Hersey M, Bacon AK, Bailey LG, Coggiano MA, Newman AH, Leggio L, Tanda G . Psychostimulant Use Disorder, an Unmet Therapeutic Goal: Can Modafinil Narrow the Gap? . Frontiers in Neuroscience . 15 . 656475 . 2021 . 34121988 . 8187604 . 10.3389/fnins.2021.656475 . free . doi .
  240. Tardelli VS, Bisaga A, Arcadepani FB, Gerra G, Levin FR, Fidalgo TM . Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis . Psychopharmacology . Berlin . 237 . 8 . 2233–2255 . August 2020 . 32601988 . 10.1007/s00213-020-05563-3 . 220150476 .
  241. Elkrief L, Sharafi H, Bakouni H, McAnulty C, Bastien G, Dubreucq S, Garel N, Trépanier A, Ziegler D, Jutras-Aswad D . Efficacy and Safety of Modafinil for Treatment of Amphetamine-Type Stimulant Use Disorder: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials . The Canadian Journal of Psychiatry . July 2024 . 39033427 . 10.1177/07067437241262967 . July 28, 2024 . August 6, 2024 . https://web.archive.org/web/20240806000510/https://journals.sagepub.com/doi/full/10.1177/07067437241262967 . live .
  242. Kane JM, D'Souza DC, Patkar AA, Youakim JM, Tiller JM, Yang R, Keefe RS . Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study . The Journal of Clinical Psychiatry . 71 . 11 . 1475–1481 . November 2010 . 20816042 . 10.4088/jcp.09m05950gry .
  243. Andrade C, Kisely S, Monteiro I, Rao S . Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials . Journal of Psychiatric Research . 60 . 14–21 . January 2015 . 25306261 . 10.1016/j.jpsychires.2014.09.013 .
  244. Correll CU, Rubio JM, Inczedy-Farkas G, Birnbaum ML, Kane JM, Leucht S . Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence . JAMA Psychiatry . 74 . 7 . 675–684 . July 2017 . 28514486 . 6584320 . 10.1001/jamapsychiatry.2017.0624 .
  245. Sangroula D, Motiwala F, Wagle B, Shah VC, Hagi K, Lippmann S . Modafinil Treatment of Cocaine Dependence: A Systematic Review and Meta-Analysis . Substance Use & Misuse . 52 . 10 . 1292–1306 . August 2017 . 28350194 . 10.1080/10826084.2016.1276597 . 4775658 .
  246. Kredlow MA, Keshishian A, Oppenheimer S, Otto MW . The Efficacy of Modafinil as a Cognitive Enhancer: A Systematic Review and Meta-Analysis . Journal of Clinical Psychopharmacology . 39 . 5 . 455–461 . 2019 . 31433334 . 10.1097/JCP.0000000000001085 . 201119084 .
  247. Roberts CA, Jones A, Sumnall H, Gage SH, Montgomery C . How effective are pharmaceuticals for cognitive enhancement in healthy adults? A series of meta-analyses of cognitive performance during acute administration of modafinil, methylphenidate and D-amphetamine . European Neuropsychopharmacology . 38 . 40–62 . September 2020 . 32709551 . 10.1016/j.euroneuro.2020.07.002 . live . 220651670 . https://web.archive.org/web/20220220101717/https://researchonline.ljmu.ac.uk/id/eprint/13268/8/How%20effective%20are%20pharmaceuticals%20for%20cognitive%20enhancement%20in%20healthy%20adults%20A%20series%20of%20meta-analyses%20of%20cognitive%20performance%20during%20acute%20administration%20of%20modafinil%2C%20methylphenidate%20and%20d-amphetamine..pdf . February 20, 2022 .
  248. 10.1136/sbmj.070256 . Anaesthesia: Induction and maintenance of general anaesthesia . 2007 . BMJ . 334 . Behar JM, Gogalniceanu P, Bromley L .
  249. Vacas S, Cole DJ, Cannesson M . Cognitive Decline Associated With Anesthesia and Surgery in Older Patients . JAMA . August 2021 . 326 . 9 . 863 . 34338712 . 8807795 . 10.1001/jama.2021.4773.
  250. 10.1097/00000542-200211000-00035 . Fatigue in Anesthesia . 2002 . Anesthesiology . 97 . 5 . 1281–1294 . 12411816 . Warltier DC, Howard SK, Rosekind MR, Katz JD, Berry AJ .
  251. 10.1097/00000542-200204000-00030 . Systematic Review and Analysis of Postdischarge Symptoms after Outpatient Surgery . 2002 . Anesthesiology . 96 . 4 . 994–1003 . 11964610 . Wu CL, Berenholtz SM, Pronovost PJ, Fleisher LA .
  252. Ballon JS, Feifel D . A systematic review of modafinil: Potential clinical uses and mechanisms of action . The Journal of Clinical Psychiatry . 67 . 4 . 554–566 . April 2006 . 16669720 . 10.4088/jcp.v67n0406 .
  253. Raj SR . The Postural Tachycardia Syndrome (POTS): pathophysiology, diagnosis & management . Indian Pacing Electrophysiol J . 6 . 2 . 84–99 . April 2006 . 16943900 . 1501099.
  254. Kohler O, Krogh J, Mors O, Benros ME . Inflammation in Depression and the Potential for Anti-Inflammatory Treatment . Current Neuropharmacology . 14 . 7 . 732–742 . 2016 . 27640518 . 5050394 . 10.2174/1570159x14666151208113700 .
  255. Zager A . Modulating the immune response with the wake-promoting drug modafinil: A potential therapeutic approach for inflammatory disorders . Brain, Behavior, and Immunity . 88 . 878–886 . August 2020 . 32311496 . 10.1016/j.bbi.2020.04.038 . 215807973 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Modafinil".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.